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in Mycobacterium tuberculosis 
 
 
Abstract 
 
Mycobacterium tuberculosis threatens global health.  Its thick, impermeable cell wall 
renders it tolerant to high doses of many antibiotics.  While we understand the biochemical 
functions of many cell wall-modifying enzymes, we often do not understand their physiological 
functions: their spatiotemporal roles in the cell cycle, their substrate preferences, or their 
individual effects on the macromolecular architecture of the cell wall complex.  Mycobacterium 
tuberculosis possesses five peptidoglycan transpeptidases, five lytic transglycosylases, and 
numerous other peptidoglycan-modifying enzymes that lack precisely-understood roles. 
 The lytic transglycosylases of Mycobacterium tuberculosis are collectively dispensable 
for in vitro growth.  We sought to learn what other classes of peptidoglycan-degrading enzyme 
might substitute for the lytic transglycosylases or become essential in their absence.  A high-
throughput chemical screen was performed on a strain lacking all five lytic transglycosylases to 
identify compounds that specifically killed this strain and not wild-type Mycobacterium 
tuberculosis.  Among the compounds identified were several members of the cephalosporin class 
of !-lactam antibiotics.  It was shown that the cephalosporins had greater access to the 
periplasmic !-lactamase of Mycobacterium tuberculosis in the lytic transglycosylase-deficient 
strain and that this strain had enhanced sensitivity to several antibiotics with unrelated 
mechanisms of action.  Together, greater periplasmic access and broadly heightened 
 iv 
susceptibility in the deficient strain suggested a role for the lytic transglycosylases in maintaining 
the mycolic acid permeability barrier. 
 To identify the specific penicillin-binding protein target of the cephalosporins, we 
isolated spontaneously-occurring resistant mutants.  These strains contained polymorphisms in 
ponA2, a bifunctional penicillin-binding protein.  The polymorphisms conferred sensitivity to 
heat stress, a phenotype associated with ponA2 loss of function.  To clarify the relation between 
loss of function and cephalosporin resistance, a ponA2 deletion strain was created, which 
exhibited both cephalosporin resistance and sensitivity to carbapenems, another class of !-
lactam.  Restoration of the wild-type ponA2 allele suppressed both cephalosporin resistance and 
carbapenem sensitivity.  Inactivation of other transpeptidases did not confer resistance to any !-
lactams.  The association of penicillin-binding protein inactivation with !-lactam resistance is 
unusual.  One model to explain it is that upon deletion of ponA2, Mycobacterium tuberculosis 
compensates for its loss by upregulating a cephalosporin-resistant, meropenem-sensitive 
transpeptidase. 
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Chapter 1: Introduction to the problem of mycobacterial 
defenses against !-lactams 
 
Section 1.1: The need for !-lactams in tuberculosis treatment 
Tuberculosis causes more than a million human deaths and $50 billion of economic 
damage each year (1).  The disease poses a continuing threat to public health because of the 
emergence of multidrug-resistant, extensively drug-resistant, and, recently, totally drug-resistant 
strains of the causative organism, Mycobacterium tuberculosis (MTB) (2). 
Standard tuberculosis treatment requires the simultaneous use of four drugs: rifampin, an 
RNA transcription inhibitor; isoniazid, a mycolic acid biosynthesis inhibitor; and ethambutol, an 
arabinogalactan biosynthesis inhibitor; pyrazinamide, a trans-translation inhibitor (3).  Trans-
translation is the process by which stalled ribosomes are recycled (4).   The side effects of the 
tuberculosis treatment regimen can be severe and may discourage many patients suffering 
tuberculosis from completing the course of treatment.  Furthermore, the six-month duration of 
the treatment makes ensuring its completion difficult in impoverished areas with poor public 
health systems (5). 
Significantly lacking from this list of drugs are any members of the antibiotic classes 
commonly used to treat respiratory tract infections: !-lactams, fluoroquinolones and macrolides 
(6), although fluoroquinolones are currently in phase III clinical trials as first-line agents (7, 8).  
The !-lactams in particular have had the longest use and greatest impact of all antibiotic classes 
against non-tubercular infections (9).  MTB possesses a strong, constitutive !-lactamase activity 
(10) that renders it highly resistant to !-lactams (11).  One potential way to overcome this 
problem is through concurrent treatment with a !-lactam and a !-lactamase inhibitor.  
Amoxicillin/clavulanate, one such combination, saw only limited success in several trials (12, 
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13).  Recently, however, the rise of multidrug-resistant tuberculosis has encouraged renewed 
interest in !-lactam/!-lactamase inhibitor combination therapy.  A recent study has shown that 
meropenem/clavulanate has potent activity against drug-resistant MTB and anaerobic models of 
persistent MTB infection (14).  This finding has led to a clinical trial for meropenem/clavulanate 
against extensively drug-resistant tuberculosis (15).  
The potential clinical use of meropenem/clavulanate, and the search for new 
antitubercular compounds in general, raise two questions.  First, what existing defenses does 
MTB have against small molecules?  Second, what are the means by which it may acquire 
further resistance?  This dissertation shall consider each of these questions in turn, primarily 
from the perspective of the !-lactams, of which meropenem and other carbapenems are a 
subclass.  Regarding existing defenses, we shall consider the complex architecture of the cell 
wall, with special emphasis on the lytic transgycosylases of MTB.  Regarding the acquisition of 
further resistance, we shall carefully review existing mechanisms of !-lactam resistance across 
bacteria and ultimately examine some intriguing mutations we have discovered in MTB. 
 
Section 1.2: Existing defenses: the mycobacterial cell wall 
The outer membrane 
Two obstacles impede meropenem in its passage through the cell wall to its 
transpeptidase target in the peptidoglycan of MTB.  First, it must traverse the hydrophobic, 
poorly permeable mycolic acid layer (16).  Then, it must escape the hydrolytic activity of MTB’s 
promiscuous, highly active !-lactamase (17).  The latter obstacle would not hinder meropenem 
by much, because meropenem is an inherently poor substrate for the MTB !-lactamase.  
Furthermore, the !-lactamase is efficiently inhibited by clavulanate in combination therapy (17). 
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The mycolic acid layer, however, bears consideration.  Mycolic acids are C60 – C90 
carboxylic acids covalently linked to arabinogalactan, an underlying polymer of repeating sugars 
(18).  This arabinogalactan layer is itself covalently bound to the peptidoglycan sacculus (19).  
Together, then, the mycolic acids, arabinogalactan, and peptidoglycan compose one giant 
macromolecule encasing the cell proper (Figure 1.1) (16). 
The mycolic acids extend some 53 to 64 carbons from a carboxylic acid head group, 
leaving the remaining carbons to form a branch extending from the carboxylic acid "-carbon 
(21).  This 53 to 64 carbon length is substantially longer than the average fatty acid in the plasma 
membrane, but recent electron microscopy studies indicate that the hydrophobic region of the 
outer mycolic acid layer is not substantially thicker than the plasma membrane, leaving some 
doubt as to the exact conformation of mycolic acids in their cellular context (22,  23).  What is 
certain is that they are generally perpendicular to the surface of the cell, and their boundary with 
the hydrophilic extracellular milieu or capsular area is mediated by a variety of accessory lipids, 
such as phthiocerol dimycocerosate and the sulfolipids, and glycolipids, such as lipomannan and 
lipoarabinomannan (24, 25).  Together, the mycolic acids on the inside and the free glycolipids 
on the outside effectively form a mycobacterial outer membrane bilayer (22, 23). 
This outer membrane forms a substantial permeability barrier to both nutrients and 
antibiotics.  For the cephalosporin class of !-lactams, by one estimate, the dual limitations of the 
permeability barrier and !-lactamase activity create a 500 to 5,000-fold concentration differential 
between the extracellular milieu and the periplasm, compared to a 1.5 to 15-fold differential 
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Figure 1.1. The unusual cell wall of Mycobacterium tuberculosis.  Peptidoglycan (PG), 
arabinogalactan (AG), and mycolic acids (MA) together compose the mycolyl-arabinogalactan-
peptidoglycan complex, a single macromolecule standing between the cell membrane (CM) and 
the extracellular milieu.  The mycolic acids also form the inner leaflet of a membrane bilayer 
separating the mycolyl-arabinogalactan peptidoglycan complex itself from the extracellular 
milieu.  Adapted from (20). 
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across the outer membrane of Escherichia coli K-12 (26).  This is true regardless of the 
hydrophobicity of the cephalosporin. 
Beyond the hydrophobicity of the mycolic acids, their unusual length and characteristic 
unsaturations also contribute to the permeability barrier they form.  There are different types of 
unsaturation, which may vary across species and contribute to the higher or lower permeability 
of the cell walls of different mycobacteria.  For instance, MTB and Mycobacterium avium 
possess a particular cis-cyclopropanated "-proximal double bond that other mycobacterial 
species lack; in direct biophysical comparisons, this modification raised the melting temperature 
of tubercular mycolic acids by 3 °C (27).  In a survey across mycobacterial species, the melting 
temperature of mycolic acid membranes rose in proportion to the average mycolic acid length for 
a given species (28).  The increases in mycolic acid melting temperature from cyclopropanation 
and elongation reflect a decrease in fluidity, which is directly related to the ability of particles to 
diffuse through the membrane (28).  These measurements, then, provide a biophysical basis from 
which to understand the importance of MTB’s outer membrane as a permeability barrier. 
Two layers of sugar polymers separate the mycolic acid layer from the cell membrane.  
The first layer, arabinogalactan, comprises a galactan chain some thirty residues in length 
followed by branching arabinan chains of similar length (29).  Notably, all of these sugar 
residues are furan isomers rather than the more common pyran isomers of other biological 
glycans (Figure 1.2).  Arabinogalactan’s higher-order structure is unknown (30).  Its biogenesis 
is not related to that of peptidoglycan, the second sugar polymer layer. 
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!-D-Galactapyranose 
 
 
 
!-D-Galactofuranose
 
 
 
 
 
"-D-Arabinopyranose 
 
 
 
 
"-D-Arabinofuranose 
Figure 1.2. Comparison of pyran and furan forms of common arabinogalactan sugars. 
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Peptidoglycan 
Mycobacterial peptidoglycan, like all peptidoglycan, is a net-like structure composed of 
polymers of N-acetylglucosamine and muramic acid crosslinked by peptide chains.  The 
peptidoglycan macromolecule is essential, confers bacterial shape, and withstands the turgor 
pressure resulting from the osmotic differential between the cell and its environment (31).  The 
enzymes responsible for its biogenesis are the targets of numerous antibiotics, including 
meropenem and other !-lactams (32).  Peptidoglycan is also of medical interest because species-
specific variations can modulate the host immune reponse to infection (33).  The diversity of 
these functions, and the diversity of the demands across bacterial species in terms of shape, 
osmotic differential, host environment, and antibiotic exposure mean that the peptidoglycan 
molecule itself is highly variable from species to species. 
The peptidoglycan of MTB must meet some unusual challenges.  It is rod-shaped, but 
elongates from its tips, in contrast to most pathogenic bacteria, which elongate from the middle 
(Figure 1.3) (34).  The peptidoglycan layer is thick, like in other Gram positive organisms, but 
must coordinate with an outer membrane, like Gram negative ones.  It is an intracellular 
pathogen, and withstands multiple innate immune insults (35, 36), but also tolerates a wide 
variety of environmental stresses (37). 
 
Peptidoglycan: the glycan chains 
The peptidoglycan that meets the diverse requirements for mycobacterial survival 
necessarily contains some unusual features.  For example, the muramic acid residues in the 
glycan chain contain a mixture of N-glycolylation and N-acetylation at C1, in contrast to the 
great majority of bacteria, which have only N-acetylation (38).  The function of glycolylation is 
 9 
 
 
Figure 1.3. Differences in peptidoglycan growth patterns between centrally and apically growing 
bacteria.  In well-studied bacteria such as E. coli and Bacillus subtilis, peptidoglycan 
polymerization and crosslinking occurs predominantly at the septum.  The age of peptidoglcyan 
(stronger shading is younger peptidoglycan) increases with distance from the septum (dotted 
line).  In mycobacteria and related genuses, such as corynebacteria and streptomyces, 
peptidoglycan polymerization and crosslinking occurs predominantly at the apices of the cell.  
The age of peptidoglycan increases approaching the septum.  Adapted with modifications from 
(34). 
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unknown, but it may play a role in modulation of the immune response.  One mechanism by 
which it could do this is by making the glycan strands resistant to degradation by lysozyme (39); 
the glycolyl modification is mere angstroms from the !-1,4-glycosidic bond that lysozyme 
cleaves, giving it the potential to affect the substrate’s interaction with the enzyme active site 
(40).  Glycolylation may have an even more basic biological role in controlling MTB’s own 
peptidoglycan-degrading activity; MTB’s genome encodes five enzymes with close homology to 
lysozyme (40, 41).  If glycolylation can alter lysozyme activity, it may alter the activity of these 
enzymes too. 
These lysozyme-like enzymes are lytic transglycosylases, which participate in another 
aspect of bacterial peptidoglycan’s structural variation.  This aspect is the modulation of glycan 
chain length.  Glycan chain length is highly variable across species (33), ranging from averages 
of tens to hundreds of disaccharides in length.  Even within individual bacterial cells (strictly, 
within clonal populations) there is a wide distribution of glycan chain lengths (42).  For 
Mycobacterium leprae, the median chain length is thought to be very short (43), but precise 
calculations do not exist for M. leprae or MTB. 
There are two ways of controlling the glycan chain length: at the polymerization stage, or 
through modification of the glycan chain after polymerization. 
In most model bacteria, the polymerizing enzyme is a high-molecular weight (HMW) 
Class A penicillin-binding protein (PBP).  Class A HMW PBPs typically contain a 
glycosyltransferase domain, which links Lipid II, a peptidoglycan precursor, to an existing 
glycan chain, and a transpeptidase domain, which crosslinks the pentapeptide side chains to 
those on other glycan chains (Figure 1.4) (44).  Beyond their direct peptidoglycan-synthetic 
functions, Class A HMW PBPs may form homodimers (45) or heterodimers (46) with other 
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Figure 1.4. Sites of action of selected peptidoglycan-modifying enzymes.  (1) is the !-1,4-
glycosidic bond, which is cleaved by lysozymes and lytic transglycosylases.  (2) is a 4!3 
peptide crosslink, which is created by HMW PBP transpeptidases and cleaved by LMW PBP 
endopeptidases.  (3) is a 3!3 peptide crosslink, which is created by L,D-transpeptidases.  (4) is a 
D-alanine-D-alanine bond in an uncrosslinked peptide pentamer, which is cleaved by LMW PBP 
D,D-carboxypeptidases; there is no theoretical reason this latter reaction cannot occur for the D-
alanine-D-alanine bond remaining on a pentamer crosslinked at its third amino acid. 
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peptidoglycan synthetic enzymes, possibly modulating their activity (47).  In addition to PBPs, 
there exist a few known independent glycosyltransferase-encoding genes with homology to the 
glycosyltransferase domains of Class A HMW PBPs (48).  These independent glycosyl-
transferases contribute significantly to the total glycosyltransferase activities of several species, 
including E. coli, Staphylococcus aureus, and Micrococcus luteus (49, 50).  MTB does not 
possess any known independent glycosyltransferases, but this does not rule out a substantial 
contribution to glycan chain polymerization from a cryptic glycosyltransferase; at least one 
Gram-positive organism, Enterococcus faecium, possesses such activity without encoding any 
genes with significant homology to known glycosyltransferase domains (51). 
There are several conceivable ways of regulating the chain length during the 
glycosyltransferase stage of peptidoglycan biosynthesis: through substrate availability, substrate 
suitability, as by the relative affinity for glycolylated or acetylated muramic acid, or through the 
processivity of the glycosyltransferase itself.  In E. coli and S. aureus, this last mechanism seems 
most important, since in vitro-reconstituted peptidoglycan biosynthesis produces polymers of 
similar lengths to those observed in vivo (52). 
The post-polymerization hydrolysis of existing polymers is important not merely for 
regulating glycan chain length, but also for peptidoglycan recycling; current E. coli models hold 
that peptidoglycan does not merely insert into laterally expanding cell walls, but moves from 
inner to outer layers in an aging process (53).  Once reaching the outer layers, peptidoglycan 
hydrolytic enzymes free the glycan chains from the sacculus and digest them before, in a well-
understood E. coli process, reimporting them into the cytoplasm (54).  Recent research has 
shown that Bacillus subtilis also possesses a peptidoglycan recycling system (55). 
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In E. coli, peptidoglycan digestion includes the complete breakdown of a chain to its 
constituent disaccharide units, requiring an enzymatic lytic transglycosylase function.  Many 
species have multiple peptidoglycan lytic transglycosylases, which may be nonessential both 
individually and in groups (56, 57).  This is also true of other enzymes involved in the 
peptidoglycan digestion, including muramidases, which release peptide side chains from the 
glycan strands, and  endo- and carboxypeptidases, which degrade the peptide side chains (Figure 
1.4) (56, 58). 
The lytic transglycosylases of MTB merit special attention because they were the initial 
focus of our research.  There are five of them (Table 1.1), and they are collectively nonessential 
for in vitro growth (60).  Since they bear little similarity to the lytic transglycosylases of E. coli, 
the first investigations into their function arose from their similarity to a protein called 
“resuscitation-promoting factor”, encoded by the gene rpf, from Micrococcus luteus (61).  This 
protein and its mycobacterial homologs were able to stimulate growth of low numbers of cells in 
broth culture, or cells collected from prolonged stationary phase incubation (61).  The finding 
that MTB had five such factors, and the similarity of the resuscitation phenomenon to the 
emergence of MTB from the latent phase of human infection, stimulated much excitement (62).  
The original model postulated that the resuscitation-promoting factors acted by binding a cellular 
receptor in a manner similar to cytokines (63).  The peptidoglycan degradatory function became 
apparent when the crystal structure of rpfB from MTB showed similarity to lysozyme (40).  The 
ability of M. luteus Rpf to digest peptidoglycan, and the dependence of both this activity and 
resuscitation from dormancy on a glutamate corresponding to a catalytic residue in lysozyme, 
established the peptidoglycan degradatory function beyond doubt (64).  Strictly speaking, it is 
not clear whether Rpf performs a lysozyme-like activity, which hydrolyses the peptidoglycan !- 
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Table 1.1. Selected peptidoglycan-modifying enzymes of Mycobacterium tuberculosis. 
 
Gene Gene Name Domainsa Essential in vitrob 
Closest E. coli 
Homologc 
Rv0050 ponA1 Glycosyltransferase Transpeptidase No Pbp1b 
Rv3682 ponA2 
Glycosyltransferase 
Transpeptidase 
PASTAd 
No Pbp1a 
Rv2163c pbpB PBP Dimerisation
e 
Transpeptidase Yes Pbp3 
Rv0016c pbpA Transpeptidase No Pbp2 
Rv2864c - Transpeptidase N-terminal
f 
Transpeptidase No Pbp2 
Rv3330 dacB1 Carboxypeptidase No Pbp6b 
Rv2911 dacB2 Carboxypeptidase No Pbp5 
Rv0867c rpfA Lytic Transglycosylase No None 
Rv1009 rpfB 
DUF348 x 3g 
G5h 
Lytic Transglycosylase 
No None 
Rv1884c rpfC Lytic Transglycosylase No None 
Rv2389c rpfD Lytic Transglycosylase No None 
Rv2450c rpfE Lytic Transglycosylase No None 
a
 Domains contained in the protein are listed from the N-terminus to the C-terminus.  Domains were determined using the PFAM 
server at pfam.janelia.org.  Domains without discriptions are discussed at length in the text. 
b
 Comprehensive descriptions of essential MTB genes are described in (59). 
c
 Homology was determined using the protein NCBI BLAST server against Escherichia coli strain K-12.  Only homologues with 
an E-value greater than 0.001 are listed. 
d
 PASTA is penicillin-binding protein and serine/threonine kinase-associated: PF03793. 
e
 This domain is found in some Class B HMW PBPs: PF03717. 
f
 This domain is found at the N-terminus of some Class B HMW PBPs, including MecA of Staphylococcus aureus: PF05223. 
g
 This is a domain of unknown function: PF03990. 
h
 This domain is found in several cell wall-associated proteins: PF07501. 
i
 A fold change of 1 indicates that there was no detectable difference between RPFnull and RPFWT. 
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1,4-glycosidic bond and consumes a water molecule, or whether it performs a lytic 
transglycosylase activity, which cleaves the bond using the muramic acid C6 hydroxyl group in 
place of water as the nucleophile (65). 
Subsequent investigation has shown that deletion of two MTB rpf homologs, rpfA and 
rpfB, attenuated resuscitation in vivo (66), while deletion of all five resulted in a severe survival 
defect in mice (60).  These defects were not associated with filamentation or morphological 
defects, which often arise from deletion of peptidoglycan-degrading enzymes.  The survival 
defects therefore highlight the importance of regulation of the peptidoglycan macromolecule 
during infection, while leaving unexplained the precise connection between the biochemical 
effects of rpf homologs and the changes these effects produce in overall cellular physiology. 
 
Peptidoglycan: the peptide crosslinks 
While glycolylation and glycan chain length vary within and across species, the most 
diversity in peptidoglycan structures arises in the peptide side chains.  These side chains are 
diverse, but MTB in particular has a “standard” side chain composition remarkably similar to E. 
coli.  Both species possess as their core, most common peptide side chain the sequence L-Ala-#-
D-Glu-meso-Dap-D-Ala-D-Ala, where meso-Dap is meso-diaminopimelic acid and #-D-Glu is 
glutamate polymerised from its #-carboxylic acid group (Figure 1.5) (67, 68).  In MTB, the 
glutamate often forms isoglutamine through amidation of the free "-carboxylic acid.  The most 
common variation on this scheme in MTB is the addition of a single glycine to the $-amino 
group on meso-Dap (67), similar to the interpeptide bridges in many Gram positive firmicutes 
(30). 
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The diversity of peptide side chains cannot match the combinatorial diversity formed by 
the crosslinking of these side chains.  Previously, models assumed that penicillin-binding 
transpeptidases carried out most or all of this crosslinking (53), and that these transpeptidases 
were the HMW PBPs.  Each HMW PBP contains a transpeptidase domain, which catalyzes the 
replacement of the peptide bond to the terminal D-Ala of a receiving pentapeptide side chain 
with the amino group from an invading peptide side chain (Figure 1.5).  This amino group is 
always contributed by the amino acid at P3 (Figure 1.5); in MTB, this is the $-amino group of 
meso-Dap, but in other species, it may be the side chain amino group of lysine or ornithine 
instead (69). 
As with glycan chain length, the degree of peptide crosslinking modulates the properties 
of the peptidoglycan macromolecule.  More crosslinking results in a finer mesh encircling the 
cell.  It also means that individual crosslinks may be less stressed, since each crosslink bears less 
of the turgor pressure of the cell contents.  This is a consequence of the greater number of 
crosslinks per unit area in a finer mesh.  The diversity of PBP paralogs in most bacterial species 
suggests transcriptional or translational mechanisms may control the amount of crosslinking that 
occurs, but other mechanisms exist as well.  Carboxypeptidases can remove the terminal D-Ala 
from a side chain, preventing it from accepting a crosslink from a neighboring peptide strand.  
Endopeptidases can hydrolyze existing peptide crosslinks, most often at P4 (Figure 1.4, Figure 
1.5).  While the P4-hydrolyzing endopeptidases are paralogs of HMW PBPs and usually non-
essential, as described above, endopeptidases have been described that cleave at nearly every 
position (70).  An endopeptidase cleaving at P2 in MTB is essential (71). 
Beyond the degree of crosslinking, the nature of the crosslink also appears to have a 
major impact on bacterial physiology.  While the invading amine group is always a side chain 
 17 
 
 
 
Figure 1.5. Peptidoglycan side chains in MTB contain L-alanine, D-isoglutate, meso-
diaminopimelic acid, D-alanine, and D-alanine.  The stereochemistry of each stereocenter is 
indicated in bold.  The possible reactive carbons to an invading nucleophile are indicated with 
electron-pushing arrows.  D-isoglutamate in MTB is often amidated, as depicted. 
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from P3, the receiving carboxylic acid can be at P4 or P3 (Figure 1.5) (68).  The former 
crosslink, termed a 4!3 crosslink, predominates in E. coli (66).  The D,D stereochemistry of the 
invading and receiving amino acid chiral centers matches the stereochemistry of the D-Ala-D-Ala 
bond they replace; these bonds are the natural substrates of PBPs (44).  In contrast, the 3!3 
crosslink, which is formed by an invading amine group from P3 forming a covalent bond with 
the "-carboxylic acid of P3 meso-Dap, predominates in Mycobacterium abscessus (72) and 
stationary phase MTB (67).  The L,D stereochemistry of the disrupted link between meso-Dap 
and D-Ala has given the enzymes catalyzing the formation of 3!3 crosslinks the name of L,D-
transpeptidases.  The investigation of 3!3 crosslinks is relatively new, but it is clear that they 
play a major role as a determinant of !-lactam sensitivity (73). 
 
Section 1.3: The !-lactam mechanism of action 
The molecular targets of the !-lactams 
The !-lactams were the first antibiotics discovered, and have to date been among the 
most successful, both in use and diversity, having spawned hundreds of semi-synthetic 
derivatives (9).  Although scientists have discovered a diverse range of bacterial resistance 
mechanisms, this dissertation will show that MTB can acquire resistance through a hitherto 
undescribed mechanism, the loss of PBP function.  To understand the details of how this 
mechanism may work, a detailed consideration of the means by which !-lactams may act is 
necessary. 
 Exposure to !-lactams may induce several different effects.  The observable outcomes 
range from bacteriostasis and morphological alterations to rapid bacteriolysis (74).  Although 
effects vary for particular species (75), antibiotics (74), and exposure conditions (76), all known 
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effects result from the inhibition of peptidoglycan-modifying peptidases outside of the cell 
membrane.  These peptidases are the (D,D-) PBPs and the L,D-transpeptidases (77). 
 The most important effects of exposure to !-lactams are cell death and bacteriolysis.  
Current models hold that cell death arises only from the inhibition of peptidoglycan-synthesizing 
HMW PBPs (67) and L,D-transpeptidases (73), as distinct from the low-molecular weight 
(LMW) endo- and carboxypeptidase PBPs, which hydrolyze peptidoglycan.  While the 
phenotypic alterations arising from deletion of the LMW PBPs indicate that they may be 
responsible for some of the morphological effects of !-lactam treatment, they are not usually 
essential (78). 
For the two most diverse classes of !-lactams, the penicillins and cephalosporins, 
bacteriolysis and cell death probably occur through inhibition of the HMW PBPs (74, 77).  
Although cephalosporin binding to the L,D-transpeptidases can occur (79), the failure to identify 
these proteins in most early assays for !-lactam binding proteins suggests the phenomenon is not 
common. 
The third major class of !-lactams, the carbapenems, also display high affinity for certain 
Class A HMW PBPs (80), and so it has been assumed that the carbapenems target these PBPs 
too (81).  Recently, the finding that carbapenems form adducts with the L,D-transpeptidases that 
form 3!3 crosslinks (82), and that they potently kill organisms rich in these crosslinks (14), has 
raised the possibility that these enzymes may present an additional or alternate molecular target 
for the carbapenems (73). 
 Whatever the relevant protein targets are in the cell, the !-lactams mimic the natural D-
Ala-D-Ala substrate of the PBPs and inhibit them by forming a slowly-hydrolyzing adduct at the 
active site (83).  The hypothesis that carbapenems may target the L,D-transpeptidases has force 
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because a distinctive feature of these carbapenems is the opposite chirality of the "-carbon 
corresponding to P4 of the peptide substrate (Figure 1.5, Figure 1.6) (81, 83).  This corresponds 
to the difference between D,D- and L,D-transpeptidation. 
 
Molecular pathways to cell death 
 The potential targets of !-lactams, then, are clear, but the means by which the inhibition 
of these targets leads to the observed effects of !-lactam exposure is less clear.  In fact, the 
precise mechanism by which !-lactams kill bacteria is an enduring mystery (77, 85, 86, 87).  The 
functional diversification of PBPs may have complicated efforts to solve the mystery, as may 
have the multiplicity of PBP paralogs in the typical bacterial genome. 
In E. coli, the best-studied system, the effects of exposure to several !-lactams have 
received comprehensive study.  !-lactams that specifically inhibit PBP3 lead to filamentation.  !-
lactams that specifically inhibit PBP2, the function of which is poorly described, induce the 
formation of ovoid cells.  !-lactams that specifically inhibit the collective PBP1 lead to rapid 
lysis (74).  The collective PBP1 comprises the PBP1a, PBP1b, and PBP1c proteins of E. coli, 
which were not separable in initial observations of the E. coli PBP complement.  PBP1a, PBP1b, 
and PBP1c are all of the Class A HMW PBPs of E. coli. 
 The bacteriolytic effect of PBP1 inhibition is consistent with a number of data indicating 
that the Class A HMW PBPs are collectively essential in many species.  This has been 
genetically demonstrated in E. coli (88) and B. subtilis (89).  In Corynebacterium glutamicum, a 
close relative of MTB with a closely corresponding set of PBPs, the deletion of its full 
complement of Class A HMW PBPs leads to severe morphological defects (90).  Why precisely 
these phenotypes should arise is not clear; both glycosyltransferase and transpeptidase activities  
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Figure 1.6. The cephalosporin and carbapenem cores have opposite chirality at the carbon " to 
the electrophilic carbonyl carbon (*).  In peptidoglycan, the corresponding "-carbon (") has 
opposite chirality at P4 and P3, where crosslinks are formed for D,D and L,D-transpeptidases, 
respectively.  The strained conformation of peptidoglycan depicted is intended to illustrate the 
correspondence; the actual conformation at a transpeptidase active site is nonetheless likely to 
force !-lactam and peptide chains into a similar correspondence, since the !-lactams are 
substrate mimics for the peptide chains. 
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are biochemically redundant, with monofunctional glycosyltransferases and Class B PBPs, 
respectively.  One hypothesis is that some Class A HMW PBPs may serve an essential 
scaffolding function (91), though whether !-lactam binding would disrupt such a function bears 
further investigation. 
 The effects of PBP3 inhibition are also consistent across species.  PBP3, also called FtsI, 
has a more distinct and well-defined function than other PBPs, as a catalyst of crosslinking 
during septal peptidoglycan synthesis.  It is recognizable across species and essential for 
septation and viability in E. coli, B. subtilis, and C. glutamicum (92, 93, 94, 95). 
 
Killing by inhibition of crosslinking 
 The simplest model for killing by !-lactams, then, is that whatever the profile of 
inhibition by low concentrations of a given !-lactam, killing effects at bactericidal concentrations 
ultimately arise from the inhibition of the well-conserved and essential functions of either FtsI or 
the collective Class A HMW PBPs (74).  The inhibition of either of these crosslinking functions 
could result in a cell wall with gradually weakening mechanical stability, which would ultimately 
succumb to the turgor pressure within the cell, rupturing violently (96, 97). 
 
Killing by autolysis 
 A finding in Streptococcus pneumoniae ultimately showed that this simple model did not 
suffice to explain the !-lactam mechanism of action.  S. pneumoniae has an autolytic system that 
causes it to undergo massive loss of viability upon reaching stationary phase (98).  The chemical 
inactivation of the major component of this autolytic system, lytA, conferred tolerance to 
penicillin (99).  The lytA gene encodes a peptidoglycan amidase (99).  Genetic inactivation of 
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amidases in E. coli (100) and endopeptidases in B. subtilis (101) confirmed that the requirement 
of !-lactam-mediated bacteriolysis for autolysins was widespread.  Notably, in all of these 
species, !-lactam tolerance was not complete; bacteriostatic, but not bacteriolytic, effects still 
occurred, and in some cases there was still a gradual loss of viability in the presence of !-lactams 
(98, 101, 102); these observations imply that either additional autolysins or another pathway of 
cell death must exist. 
The requirement for autolysins led to the balanced growth model of killing by !-lactams 
(103).  In this model, the proper maintenance of peptidoglycan requires a balance of synthetic 
activities, primarily from PBPs, and lytic activities from autolytic peptidoglycan hydrolases; 
inhibition of PBPs by !-lactams tips the balance in favor of the lytic activities, and the cell wall 
gradually degrades until it is too weak to withstand the turgor pressure of the cell, resulting in 
release of cytoplasmic contents and death (103). 
 
Killing by induced autolysis 
This model has endured to the present as a partial explanation of !-lactam killing (104).  
The most significant refinement to the model has been the realization that autolysins are under 
close control and depend on cellular signals to perform !-lactam-mediated bacteriolysis (103).  
This refinement sprang from two lines of evidence.  First, in E. coli, B. subtilis, S. pneumoniae, 
S. aureus, and E. faecium, manipulation of culture conditions could uncouple PBP inhibition and 
bacteriolysis in time (105, 106), demonstrating that the autolysins require a particular signal or 
condition to be active.  Second, even in autolysis-defective bacteria, growth and sometimes even 
division continue normally (56, 99, 100, 101), which shows that other, redundant peptidoglycan-
hydrolyzing enzymes must exist, insofar as peptidoglycan hydrolysis is necessary for normal 
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growth.  The necessity of some form of peptidoglycan degradation is a feature of current models 
of peptidoglycan maintenance (53, 107).  Therefore, even with autolysins deleted, there must be 
other peptidoglycan degradatory machinery active.  These other, redundant peptidoglycan-
hydrolyzing enzymes must act under different conditions than the penicillin-induced autolysins, 
again implying that the cell restricts or activates at least one of the two groups – the autolysins, 
or the other enzymes. 
Both of these observations show that the cell can, under some conditions, control the 
activity of autolysins (103).  For the Gram positive organisms, an elegant model exists wherein 
the local acidity of cell wall regions controls hydrolase activity (108).  Several factors in turn 
modulate this local acidity: the buffering capacity and pH of the extracellular milieu, the proton 
motive force, and the D-alanylation of teichoic acids.  The balance of these forces can cause fine-
tuned local variations across the cell wall (108).  This model is more problematic for E. coli, 
which lacks teichoic acids and the thick peptidoglycan of Gram positive organisms, which are 
critical features of the model (108). 
 
Killing by holins 
 The balanced growth model does not explain cell death that occurs without bacteriolysis, 
which occurs in some streptococci (109, 110).  In these systems, loss of colony-forming ability 
and protein and RNA synthesis occur without any detectable change in optical density.  In the 
initial report of this phenomenon, an uncharacterized mutation reduced this cell death by four 
orders of magnitude (109). 
 The identity of this mutation did not become clear until years later, when other 
researchers found a mutation in the cidAB operon of S. aureus conferring a similar amount of !-
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lactam resistance.  CidA bears homology to holin proteins, and its deletion lowered the 
extracellular peptidoglycan hydrolase activity of S. aureus mutants (111).  Holins are small 
proteins that tend to disrupt the cell membrane; their effect here on extracellular peptidoglycan 
hydrolase activity is consistent with their usual function in phage infection.  In phage infection, 
peptidoglycan hydrolases remain intracellular, where they cannot act, until the appropriate point 
in the infection cycle.  At the appropriate point, the balance of holins and antiholins changes to 
permeabilize the cell membrane; the released hydrolases digest the peptidoglycan, and packaged 
phage can diffuse freely through the permeabilized membrane and digested peptidoglycan to 
infect other cells (112). 
 Notably, while endogenous holins evidently perform the same biophysical function in S. 
aureus during !-lactam-induced death as phage-encoded holins do during phage escape, the 
method of killing to which endogenous holins contribute is non-lytic, indicating that it does not 
require the release of peptidoglycan hydrolases.  Instead, cell death may occur simply as a result 
of the collapse of the cell membrane permeability barrier, followed by loss of the proton motive 
force and dissipation of the cellular machinery (108, 110).  Consistent with this model, the 
antiholin regulator of cidAB, lrgAB, activates in response to decreases in the proton motive force, 
allowing it to prevent inappropriate killing by cidAB-mediated permeabilization (113). 
 Homologs of cidAB occur in E. coli and many Gram positive bacteria, but there are no 
obvious homologues in MTB or other actinomycetes.  This is not surprising, because the 
prevailing explanation for the existence of cidAB is that it has a role in biofilm development 
(108); the holins facilitate the release of DNA from dying staphylocci, which increases biofilm 
integrity (114).  The exploration of biofilm roles in MTB pathogenesis is still in its infancy, but 
biofilms do not play a role in the classical model of granulomatous infection.  Although, MTB 
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lacks obvious cidAB homologs, the possibility that some such system may contribute to !-
lactam-mediated cell death cannot be excluded, since the holins are merely small, amphiphilic 
helical proteins, and proteins meeting this description are abundant in MTB’s genome (41). 
 
Killing by oxidative damage 
Another recent proposal is that killing by !-lactams may occur through the disregulation 
of the tricarboxylic acid cycle and the Fenton reaction, leading to widespread, lethal hydroxyl 
radical damage to all cellular macromolecules (115).  The precise contributions of this pathway 
to killing, and the causal role of hydroxyl radical damage in this killing, require additional work 
(115, 116), but the very existence of widespread internal damage during exposure to !-lactams 
reinforces a crucial point: the existence of pathways to cell death involves sensing of !-lactams. 
 
Cellular sensing of !-lactams 
The oxidative damage pathway, the holin:antiholin pathway, and the induced autolysis 
pathway to bacterial cell death all require some means by which the cell can sense the state of its 
peptidoglycan, or sense the presence of !-lactams directly.  Without signal transduction, the 
active processes in these pathways would never be initiated. 
There are several possible mechanisms the MTB cell could use to monitor the state of its 
peptidoglycan synthetic machinery.  One mechanism is through a sensor protein.  S. aureus uses 
such a mechanism, the BlaR1 protein, to monitor !-lactam concentrations so that it can avoid 
unnecessary expression of its supplementary, highly !-lactam-resistant PBP, PBP2a.  PBP2a is 
the principle effector of methicillin resistance in methicillin-resistant S. aureus infection.  To 
respond to treatment with methicillin, a sensor domain resembling a transpeptidase domain 
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resides outside the cell, connected by a transmembrane helix to an internal peptidase domain that 
controls the expression of PBP2a, upregulating it when !-lactams are present (117).  MTB has a 
close homolog of BlaR1.  This gene, Rv1845c, is thought to respond to !-lactams, but has only a 
BlaR1-like response domain, with no sensor domain (118).  MTB nonetheless possesses many 
candidate domains that may bind to !-lactams, including a number of !-lactamases and 
undescribed transpeptidases not thought to contribute directly to !-lactamase activity.  It also 
possesses two genes that encode the PBP-associated serine and threonine kinase-associated 
domain, a specialized domain that may bind peptidoglycan-like substrates and play a role in 
sensing (119).  It is possible that any of these proteins may interact with BlaR1 or another 
transmembrane regulator to convey direct information about the presence of !-lactams. 
 Another mechanism through which MTB may sense the presence of !-lactams is 
indirectly, by monitoring the state of its peptidoglycan.  One way to do this would be through the 
peptidoglycan recycling pathway, by which various peptidoglycan fragments are transported 
directly to the cytosol.  In E. coli, this pathway provides information through the proportion of 
tri-, tetra-, and pentapeptides imported by AmpD, a disaccharide-peptide transporter.  An 
increased ratio of pentapeptides to tripeptides indicates a lack of PBP activity, implying the 
presence of !-lactams and leading to expression of the AmpC !-lactamase (120).  While MTB 
does not possess clear homologs to the proteins of the Amp pathway, it and other Gram positive 
bacteria evidently do have a peptidoglycan recycling system, as indicated by the description and 
characterization of the NagZ protein in B. subtilis (55).  Investigation into this system is only 
beginning.  MTB possesses a NagZ ortholog (41). 
 Finally, bacteria may possess additional ways of sensing !-lactams by somehow directly 
monitoring the activity or inhibition of their !-lactam sensitive transpeptidases.  In C. 
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glutamicum, which is closely related to MTB, depletion of FtsI (a Class B HMW PBP), but not 
its inhibition by cephalexin, resulted in overexpression of the structural protein DivIVA (95).  
The overexpression of this protein implies that cephalexin-bound FtsI activates some signaling 
pathway distinct from the one activated by absence of FtsI activity, which does not lead to 
DivIVA overexpression.  Since FtsI activity is absent in both cases, there should be no difference 
that can be detected from the state of the peptidoglycan itself.  C. glutamicum, which falls in the 
same actinomycete family as MTB, may possess a sensor molecule like BlaR1 or may have some 
entirely novel way of monitoring FtsI activity.  
 FtsI may represent a special case; unlike most PBPs, it is individually essential in most 
species and well-conserved across all species (92).  There is more evidence that there may be 
distinct cellular signaling pathways to monitor FtsI.  In E. coli, cells appear to be able to react to 
FtsI inhibition by turning on the SOS response and inducing the dpiBA operon (121); as with C. 
glutamicum, the specific mechanism of signaling is not known (121). 
 
Section 1.4: Potential defenses: !-lactam resistance across bacteria and its implications for 
mycobacteria 
 Given the uncertainty surrounding the precise series of steps by which exposure to !-
lactams leads to bacterial cell death, it would be remarkable if there existed a complete catalog of 
the mechanisms by which bacteria might acquire resistance to the !-lactams.  Nonetheless, two 
broad classes of resistance mechanisms have occurred over and over again (Figure 1.7).  The 
first broad class contains those mechanisms that decrease the effective concentration of !-lactam 
at the general site of action, the periplasm or cell wall zone.  This class comprises changes in 
outer membrane permeability, changes in !-lactamase activity, and changes in efflux pump  
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Figure 1.7. Overview of !-lactam resistance mechanisms.  A simplified mycobacterial cell wall 
is depicted from the outer membrane (OM) through the peptidoglycan (PG) to the cell membrane 
(CM).  In the bottom panel, the same cell wall is depicted after having utilized the full 
complement of resistance mechanisms discussed here: [1] alterations in permeability of the outer 
membrane; [2] increase in efflux pump expression; [3] increase in !-lactamase expression; [4] 
target site modification of the constitutive PBP; [5] and expression of a new, !-lactam refractory 
PBP. 
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activity.   The second broad class of !-lactam resistance mechanisms is the modification of the 
PBP profile of the cell in such a way that sufficient transpeptidase activity exists for survival at a 
given !-lactam concentration, where before it had not.  This may occur through target site 
modification, in which an individual PBP acquires a mutation altering its affinity for !-lactam 
substrates, or through acquisition or expression of previously unused PBPs with low !-lactam 
affinity. 
 
Permeability 
 Changes in outer membrane permeability could occur by diffusion through the 
hydrophobic bilayer itself or through alterations in the population of porins it contains (122).  In 
Pseudomonas aeruginosa, which like MTB has a combination of permeability and efflux 
defenses (123), !-lactam diffusion through porins is much more important than direct diffusion 
across the lipid bilayer: increasing !-lactam hydrophobicity leads to decreasing effectiveness, 
since the increased bilayer diffusion does not compensate for loss of mobility through porins.  
Therefore, although both alterations in porin content (124) and outer membrane composition 
(125) correlate with acquisition of !-lactam resistance, outer membrane changes probably act 
through the populations of porins that are permitted in the outer membrane (122, 125). 
 MTB is similar to Gram negative organisms, in that it possesses a well-defined outer 
membrane with porins for nutrient diffusion.  Also like Gram negatives, diffusion of !-lactams 
into MTB probably occurs through hydrophilic pathways rather than across its lipid bilayer (26).  
Since few model Gram positive organisms possess similar outer membranes to MTB, and against 
these few, !-lactams are generally ineffective, little literature exists on the possibility of MTB 
modifying its porin or outer membrane characteristics to resist !-lactam diffusion through its 
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hydrophilic entry points.  Expression of a porin from a closely related organism, Mycobacterium 
smegmatis, in the MTB model Mycobacterium bovis BCG, increased growth rate and sensitivity 
to several antibiotics, implying that low hydrophilic diffusion is a limiting factor in growth (126, 
127), and that further diminution of these pathways could not increase !-lactam resistance 
without deleteriously affecting growth.  Notably, however, some research has identified loss of 
function mutations in sulfolipid biogenesis genes that appear to confer !-lactam resistance in 
MTB.  Sulfolipids are components of the outer membrane.  This research only showed genetic 
association, and did not identify changes in the sulfolipid population, or show a causal link 
between gene loss and resistance (128); nonetheless, the possibility exists that diffusion across 
the lipidic components of the outer membrane does play an unappreciated role in !-lactam access 
to the periplasm. 
 
!-lactamase activity 
The second method of altering effective !-lactam concentration is through alteration of 
the !-lactamase profile.  MTB possesses a strong, promiscuous !-lactamase, BlaC (129), and 
numerous apparent !-lactamase paralogs (41) with undefined activity; not all are necessarily !-
lactamases.  The blaC gene itself is under control of at least two stress-responsive transcription 
factors (118).  Together, these factors suggest a broad potential for MTB to alter its existing !-
lactamase transcription levels and substrate specificities through spontaneous mutation.  MTB 
has not yet realized this potential in the clinic; a broad survey of clinical strains found little 
variation in the !-lactamase activities present (130). 
 Despite this potential, MTB lacks one of the most important resistance determinants for 
the carbapenem class of !-lactams.  Metallo-!-lactamases, which tend to have extremely broad 
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substrate specificity, activity against carbapenems, and resistance to standard !-lactamase 
inhibitors (131), are not present in the MTB genome.  MTB is unlikely to acquire one of these 
genes, because despite their recent spread in other organisms, MTB has very low potential for 
horizontal gene transfer (132, 133).  This removes one of the most serious potential weaknesses 
of the tuberculosis therapy highlighted by this review, treatment with meropenem/clavulanate. 
 
Multidrug efflux pumps 
 The third method of altering effective !-lactam concentration is through multidrug efflux 
pumps.  Multidrug efflux pumps are a widespread mechanism of antibiotic resistance.  In the 
case of MTB and other organisms possessing an outer membrane, all of the multidrug efflux 
pump families require adaptor proteins to facilitate transport from the cytoplasm or periplasm 
across the outer membrane.  Although MTB does not possess homologs to the known adaptor 
proteins (41, 134), it does possess numerous multidrug efflux pumps (128).  One of these exports 
!-lactams, and its loss confers !-lactam sensitivity (128).  Together, these findings suggest that 
transcriptional alteration of efflux pump profiles has great potential to confer additional !-lactam 
resistance. 
 
Target site modification 
 The second broad class of mechanisms of !-lactam resistance is modifications of the 
transpeptidase activity that allow it to evade !-lactam binding.  The most prominent method for 
doing this is through target site modification, which can make a PBP more refractory to a given 
!-lactam.  Target site modification may work through two methods.  First, point mutations in the 
target site may alter the deacylation rate, allowing the PBP to eject the suicide substrate and 
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regain its functionality on a short timescale.  Such mutations confer modest resistance in S. 
pneumoniae (135).  Second, point mutations can alter the affinity – the quotient of the acylation 
rate constant for the !-lactam divided by its dissociation constant for the PBP in question – of the 
PBP, resulting in an improved ratio of peptidoglycan to !-lactam binding (77).  While target site 
modification often occurs through genetic exchange and the formation of mosaic alleles differing 
by as much as 15% from the original parent alleles (136), target site modification by genetic 
exchange would likely be unavailable to MTB because of its low potential for horizontal gene 
transfer.  Instead, it would have to acquire resistance through individual point mutations.  Such 
mutations can confer modest resistance to !-lactams.  Like all target site modification of PBPs, 
point mutations are usually dominant (77, 137). 
 
Alteration of the penicillin-binding protein profile 
Instead of altering an existing transpeptidase through target site modification, the cell 
may acquire or express a new PBP.  The most prominent example of this sort of resistance is 
PBP2a in S. aureus.  PBP2a has very low affinity for many !-lactams (138), but is sufficient to 
carry on transpeptidation when all other PBP transpeptidase functions are inhibited (139).  
PBP2a is inducible by a !-lactam-sensing system (117), and its expression does not alter the 
remainder of the PBP profile of the cell (140), which is intuitively consistent with its dominant 
mode of action (137); expression of nonfunctional homologs does not interfere with the action of 
the dominant PBP. 
 S. aureus acquired PBP2a from a mobile genetic element (141); the possibilities for MTB 
acquiring PBP2a or a similar resistance mechanism are therefore limited by MTB’s low potential 
for horizontal gene transfer.  Nonetheless, the fact that PBP2a is repressed under normal 
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conditions illustrates an important point: MTB may not express its entire complement of PBPs 
except under stressed conditions.  Some have hypothesized that ponA2, a Class A HMW PBP, 
may have special sterically obstructive elements that render it refractory to !-lactam binding 
(44), and experimentally, PonA2 does bind to some !-lactams poorly (142).  Our laboratory has 
noted that PonA2 seems to express poorly at the translational level, perhaps because it is not part 
of the housekeeping peptidoglycan biosynthesis machinery under !-lactam-diminished 
conditions (unpublished data).  PonA2 is therefore a speculative example of the potential for a 
PBP2a-like resistance mechanism in MTB. 
 A relatively unexplored mechanism of resistance that fits broadly into alteration of the 
PBP profile is the replacement of normal crosslinking functions with L,D-transpeptidation in E. 
faecium.  In this mechanism, under inhibition by !-lactams, PBP crosslinking stops, while L,D-
transpeptidation continues.  An unusual feature of this system is that the L,D-transpeptidase does 
not take the usual pentapeptide as a substrate; instead, it exclusively uses tetrapeptide, which 
must be created from pentapeptide by a !-lactam-insensitive D,D-carboxypeptidase (143, 144).  
There is no energetic or biophysical reason why tetrapeptide should be the required substrate; 
this requirement appears to be a result of the substrate preference of the E. faecium L,D-
transpeptidase.  Therefore, although MTB does not possess any orthologs of the E. faecium 
carboxypeptidase (41), it does possess several L,D-transpeptidases, and so it is conceivable that it 
could acquire resistance through L,D-transpeptidation. 
 This experiment in E. faecium is distinctive in that it shows a mechanism of !-lactam 
resistance that relies on loss of PBP function, and loss of dependence on this function, rather than 
gain of it in the face of increasingly harsh exposures to !-lactams.  The authors obtained this 
distinctive resistance phenotype by five serial passages (144).  In this dissertation, we hope to 
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show the generation, in a single step, of a mutant that may rely on a similar mechanism, and that, 
in any case, confounds all of the above explanations for !-lactam resistance. 
 
Section 1.5: Dissertation overview 
 Our interest in the cell wall began with the resuscitation-promoting factors of MTB; we 
thought the essential role during infection of a class of peptidoglycan-modifying enzymes that 
otherwise lacked obvious phenotypes intriguing.  In Chapter 2, we use a high-throughput 
chemical screen to identify compounds that specifically kill MTB lacking resuscitation-
promoting factors.  One of the most prominent classes of compounds that does so is the 
cephalosporin class of !-lactams.  In Chapter 3, we further investigate the cephalosporins in 
detail.  We show that cephalosporins have increased potency against the resuscitation-promoting 
factor-deficient strain because of a permeability defect in its mycolic acid layer; we propose that 
this permeability defect may explain the importance of the resuscitation-promoting factors 
during infection. 
 In Chapter 4, we investigate the physiologically relevant target of the cephalosporins.  
We show that spontaneous resistance arises from mutations in the ponA2 Class A HMW PBP.  
These mutations confer partial loss of function in the transpeptidase domain and to lead to 
meropenem sensitivity as well as cephalosporin resistance.  We propose a model of ponA2 loss 
of function-mediated resistance wherein PonA2 activity is replaced by the activity of a 
cephalosporin-resistant, meropenem-sensitive transpeptidase. 
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Chapter 2: Chemical genetics reveals a broad vulnerability 
in resuscitation-promoting factor-deleted Mycobacterium 
tuberculosis 
 
Section 2.1: Abstract 
 The bacterial cell wall has provided many of the most successful targets for antimicrobial 
compounds, while remaining a fertile area for investigations into bacterial physiology.  One such 
investigation identified the resuscitation-promoting factors of Mycobacterium tuberculosis as 
collectively dispensable for in vitro growth but essential for survival during infection of a host.  
The resuscitation-promoting factors are predicted to encode lytic transglycosylases.  We sought 
to probe the function of these genes using a chemical synthetic lethal screen.  A diverse library of 
known bioactive, commercial, natural isolate, and diversity-oriented synthesis compounds was 
screened for the ability to selectively inhibit growth of a strain lacking the resuscitation-
promoting factors but not wild-type M. tuberculosis.  Several diversity-oriented synthesis 
scaffolds showed activity across multiple compounds, but the inhibition of wild-type M. 
tuberculosis by similar compounds, the lack of stereospecificity in the scaffolds, and the activity 
of some compounds in an erythrocyte lysis assay led to the conclusion that these compounds did 
not act through inhibition of a synthetically essential enzymatic process.  Among the known 
bioactive compounds, 9 out of 31 !-lactams screened showed resuscitation-promoting factor 
specific activity.  Slight sensitization to known bioactive compounds with unrelated mechanisms 
of action, such as rifampin and the macrolides, suggested that the increased activity was the 
result of a broad permeability defect caused by the deletion of the resuscitation-promoting 
factors, rather than synthetic lethal interactions with specific genes. 
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Section 2.2: Introduction 
Chemical biology provides a number of useful advantages that complement classical 
approaches to understanding bacterial physiology.  Among these are the ability to rapidly and 
reversibly inhibit a protein target, to perturb the function of essential genes, and to modulate 
enzymatic activity in biologically relevant niches, such as during host infection (1).  We thought 
these tools would be advantageous in studying the resuscitation-promoting factors of 
Mycobacterium tuberculosis, which are a recently identified family of cell wall-acting enzymes 
(2, 3). 
Chemical genetics is uniquely appropriate for molecular biological examinations of the 
cell wall.  Each class of cell wall-modifying enzymes – transpeptidases, carboxypeptidases, lytic 
transglycosylases, endopeptidases, and amidases – typically has multiple paralogs in any given 
species (4, 5, 6).  This redundancy makes classical genetic approaches to understanding gene 
function difficult and time-consuming.  The difficulty arises not merely from the large number of 
potential paralogs for a given function, but also from the fact that these paralogs may not be 
identifiable in advance.  For example, endopeptidases and carboxypeptidases may both have 
annotations as low-molecular weight penicillin-binding proteins, and in fact some of these 
proteins may perform both enzymatic activities (7).  This lack of clarity necessitates a laborious 
combinatorial approach to generate mutants with informative phenotypes (8). 
Chemical genetics, in contrast, can sometimes provide a single small molecule, like !-
lactams for the transpeptidases, or 2-nitrophenylthiocyanates for the lytic transglycosylases of 
MTB (9), that can reversibly or irreversibly inactivate a whole class of proteins without genetic 
manipulation.  With attention to dosing, single small molecule inhibitors can behave either as 
specific inhibitors of individual paralogs, or as general inhibitors of a class (10).  Chemical 
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genetics also provides a facile approach to study the components of the extracellular 
peptidoglycan maintenance machinery that are essential, such as FtsI; cephalexin and piperacillin 
are specific inhibitors of this essential protein in E. coli (11). 
 Mycobacterium tuberculosis (MTB) in particular benefits from a chemical genetic 
approach, because classical genetic studies remain difficult, since even a modest amount of 
laboratory growth can lead to loss of mycobacterial virulence factors (12).  Such losses can alter 
mycobacterial physiology in unpredictable ways.  Moreover, MTB’s 18-24 h doubling time can 
make the generation of a mutant strain fully deleted for a family of paralogs take years (13, 14, 
15). 
**MTB is the causative agent of tuberculosis and resists killing by many antibiotics.  
This resistance arises partly from the unique mycobacterial long-chain mycolic acids that are 
covalently bound to the cell wall peptidoglycan by intermediate arabinogalactan polymers, 
encasing the bacterium in a poorly permeable, hydrophobic shell.  Bacteria regulate growth and 
division using many classes of peptidoglycan-modifying enzymes to remodel the cell wall, 
including, in MTB, the five resuscitation-promoting factors (rpfA-E), which are thought to 
correspond to peptidoglycan lytic transglycosylases in Gram-negative organisms.  Like lytic 
transglycosylases, RPFs are not essential for in vitro growth.  Thus, deletion of all five RPF 
homologues (H37Rv&rpfACDEB, hereafter RPFnull) in MTB has no effect on bacterial viability 
in broth culture, although one growth model on an agar support shows delayed colony formation 
(15).  In contrast, the RPFs are essential for growth and persistence in a mouse model of MTB 
infection (15).  Since cell wall growth and division can apparently proceed in vitro in the absence 
of RPFs, it is unclear what their essential role is in vivo. 
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Homology studies, demonstrated enzymatic activity (16), and interactions with other cell-
wall modifying enzymes (17) all suggest that RPFs have a function modifying peptidoglycan.  
Because of the covalent interaction between the peptidoglycan and the mycolic acids, alterations 
to peptidoglycan may affect the outer membrane, the integrity of which contributes to hallmark 
mycobacterial characteristics, including clumping of cells in culture, impermeability, and broad 
antibiotic tolerance.  RPFs may therefore contribute to these characteristics. 
In order to elucidate further roles of the RPFs in M. tuberculosis, we performed a high-
throughput chemical screen of 26,000 compounds to identify molecules that preferentially inhibit 
growth of RPFnull but not wild-type M. tuberculosis (RPFWT), thus providing a synthetic lethal 
phenotype with the RPFs.** 
 
Section 2.3: Results and discussion 
Chemical screen and selection of hits 
We designed a high-throughput chemical screen for logarithmically growing RPFnull in 
384-well format.  Growth of RPFnull in the presence of diverse small molecules was measured 
after four days, using constitutively-expressed red-fluorescent protein.  A total of 26,000 
compounds were screened. 
**The results from the screen against RPFnull were compared to results from a parallel 
screen against RPFWT (18).  We selected for follow-up 168 compounds that were hits against 
RPFnull but not RPFWT; hits were defined as those compounds whose mean activity exceeded the 
activity of rifampin at a concentration at which the Z! of rifampin, equaled zero (19).  Rifampin 
is a tuberculocidal antibiotic that provided clear killing and was used as a control in the screen; 
Z! is a measure of separation between negative and positive controls.  An additional 42  
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Figure 2.1. Selection of compounds from an RPF synthetic lethal screen.  Selection of 
compounds that were designated hits (red) from the entire population of screened compounds 
(blue) was performed using two methods.  First (left), hits were selected for which activity 
exceeded a predefined threshold (see text) in the strain of interest, RPFnull, but not in RPFWT.  
Second (right), hits were selected for which the difference in growth between RPFWT and RPFnull 
exceeded an arbitrary threshold.  There was overlap between the selection methods. 
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compounds were selected for which the pairwise difference in growth for each molecule between 
RPFWT and RPFnull exceeded an arbitrary threshold (Figure 2.1).  Some compounds with 
significant differences in activity between the two strains may not have been identified because 
the screening concentration exceeded the inhibitory concentration of both strains.** 
Each of the selected compounds was retested against RPFnull and against 
H37Rv%rpfACBED, an alternatively-derived RPF knockout strain (Table 2.1).  This second 
strain was used as a biological replicate, to eliminate concerns that secondary mutations arising 
from the lengthy passaging of RPFnull during its creation might be contributing to vulnerability to 
the RPFnull-inhibitory compounds.  The strains were also tested against the parent strain, RPFWT; 
this strain differs from H37Rv because it lacks phthiocerol dimycocerosate (PDIM) (Table 2.1) 
(20), a virulence factor known to influence the mycobacterial permeability barrier to some small 
molecules (21). 
The retest was performed using the screening methodology, at full or half screening 
concentration, depending on compound availability.  Compounds were also retested at five 
twofold dilutions below the maximum dose to evaluate their potency.  Of the retested 
compounds, 76 were eliminated because they had similar activity against RPFWT and RPFnull, 
indicating that either they had undetected activity in the original screen against H37Rv, or that 
their activity against RPFnull was a result of PDIM deficiency, not the loss of RPFs.  The cutoff 
for elimination corresponded to about 33% inhibition of RPFWT growth. 
Culling the remaining 134 compounds to an interpretable list presented a significant 
challenge, with 36 data points (2 duplicates " 3 strains " 6 doses) per compound.  Three criteria 
were of importance: potency, reproducibility, and specificity.  The former two factors were 
evaluated by mean effect size and the tendency of graded inhibition to occur at lower doses, 
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Table 2.1. Strains used in this work. 
 
Name Description Source 
Mycobacterium 
   tuberculosis 
   H37Rv 
Laboratory strain E Rubin 
H37Rv PDIM- 
   (RPFWT) 
Alternate lineage of H37Rv containing a frameshift mutation in mas, 
   which is required for biosynthesis of phtiocerol dimycocerosate. V Mizrahi 
H37Rv%rpfA H37Rv PDIM- containing an unmarked deletion of the gene rpfA (13) 
H37Rv%rpfB H37Rv PDIM- containing an unmarked deletion of the gene rpfB (13) 
H37Rv%rpfC H37Rv PDIM- containing an unmarked deletion of the gene rpfC (13) 
H37Rv%rpfD H37Rv PDIM- containing an unmarked deletion of the gene rpfD (13) 
H37Rv%rpfE H37Rv PDIM- containing an unmarked deletion of the gene rpfE (13) 
H37Rv%rpfAB H37Rv%rpfA containing an unmarked deletion of the gene rpfB (13) 
H37Rv%rpfACD H37Rv%rpfA containing an unmarked deletion of the genes rpfC and rpfD (14) 
H37Rv%rpfACBE H37Rv%rpfA containing an unmarked deletion of the genes rpfA, rpfB, and    rpfE (15) 
H37Rv%rpfACDE H37Rv%rpfACD containing an unmarked deletion of the gene rpfE (15) 
H37Rv%rpfACDB H37Rv%rpfACD containing an unmarked deletion of the gene rpfB (15) 
H37Rv%rpfACDEB 
   (RPFnull) H37Rv%rpfACDE containing an unmarked deletion of the gene rpfB (15) 
H37Rv%rpfACBED H37Rv%rpfACBE containing an unmarked deletion of the gene rpfD (15) 
H37Rv%rpfACDEB:: 
   pHrpfCDE 
H37Rv%rpfACDEB with rpfC, rpfD, and rpfE under the control of their 
   native promoters on the integrating plasmid pHINT this work 
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while specificity was evaluated by inhibition of RPFWT.  These criteria were transformed into a 
set of selective rules. 
1. The compound must have an effect size of at least 33% inhibition of growth at the 
maximum dose. 
2. The compound must have a non-zero effect size at the second-highest dose. 
3. The compound must have more inhibition of the RPFnull than of RPFWT at the maximum 
and second-highest doses. 
In all, 47 compounds remained after this selection process (Table 2.2). 
 
Follow-up with H37Rv#rpfE and H37Rv#rpfAB 
 We wished to understand whether all of the RPFs shared one collective function, or 
whether they had specific, individual functional roles.  In particular, we wondered whether one 
or two RPFs might play a dominant role in sensitization to various small molecules, with the rest 
being irrelevant.  To answer this question, we decided to investigate whether RPF-dependent 
resistance to the small molecules described above was typically dependent on the presence of 
individual RPFs or on the class of genes as a whole.  If RPF-dependent resistance was dependent 
on individual RPFs, we would expect some single RPF knockouts to display the same increases 
in sensitivity to certain small molecules that RPFnull displayed.  If, on the other hand, RPF-
dependent resistance could be conferred by any RPF, regardless of its genetic origin, we would 
expect single knockouts to be broadly resistant, with most compounds being only effective 
against RPFnull. 
 Due to limitations on the amount of many compounds available, only two additional RPF 
strains could be tested.  Strains H37Rv%rpfAB and H37Rv%rpfE were selected because it is  
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Table 2.2. Selection of hits from high-throughput chemical screening of RPFnull. 
 
Type of Selection Number of Compounds 
Compounds screened 26000 
Cherry-picked for further analysis 210 
Inactive against H37Rv PDIMnull 134 
Selected by for high potency 47 
Of which  
      Active against H37Rv%rpfAB and H37Rv%rpfE 16 
       Active against H37Rv%rpfAB and not H37Rv%rpfE 2 
       Active against H37Rv%rpfE and not H37Rv%rpfAB 1 
       Active against H37Rv RPFnull only 28 
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believed that rpfA, rpfB, and rpfE are more likely to have singular functional roles than rpfC and 
rpfD.  This belief is predicated on the greater size of the former genes and their greater 
importance in several phenotypes (15).  For example, rpfB contains several accessory domains 
that appear to help it achieve localization or substrate specificity, and an rpfB knockout has a 
delayed-growth phenotype in a mouse model of latent infection (22). 
 Strains H37Rv%rpfAB and H37Rv%rpfE were tested as above for RPFWT and RPFnull: 
compounds were tested against strains over a six-point dose-response curve for each compound, 
beginning at the concentration used for the original high-throughput screen, which was between 
5 and 10 µM for most compounds. 
 The majority of the compounds, 28 out of 47 (Table 2.2), were ineffective against any 
strain studied except RPFnull.  This result was consistent with the hypothesis of broad functional 
redundancy among the RPFs. 
 More surprisingly, 16 out of the 47 were effective against all three strains: RPFnull, 
H37Rv%rpfE and H37Rv%rpfAB.  This finding was not strictly consistent with either the 
hypothesis of broad functional redundancy or of specific roles for specific RPFs.  Rather, it 
implies that rpfE shares a broad functional role with either rpfA or rpfB, but cannot replace their 
individual activities.  The conclusion that the genes share a broad functional role follows from 
the fact that loss of rpfA/rpfB and loss of rpfE lead to the same phenotype: sensitization to the 16 
small molecules.  The conclusion that sharing a broad functional role, they do not act in the same 
specific functional niches follows from the fact that rpfA/rpfB cannot completely compensate for 
rpfE or vice versa; instead, each of these 16 compounds can inhibit a strain that has lost either 
rpfA/rpfB or rpfE. 
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Discussion of chemical properties of hits 
!-lactams 
 Out of 31 !-lactams screened, 9 had specific activity against RPFnull.  Two others had 
specific activities that were not detected in the screen because the screening concentration was 
not high enough.  There was no obvious molecular profile of physical properties that 
distinguished those compounds with activity against RPFnull from those without; among the 
physical properties considered were hydrophobicity, polarity, molecular weight, charge state, and 
the presence of acidic or basic sites (Figure 2.2).  All of the !-lactams contained the 
cephalosporin core, except cloxacillin.  This !-lactam had a bulky residual group in common 
with the cephalosporin hits, but such residual groups are common across !-lactams (Figure 2.3). 
 
Tuberculocidal diversity-oriented synthesis compounds 
 Out of the 47 compounds, 24 were members of three classes of DOS (diversity-oriented 
synthesis) compounds.  DOS compounds are designed to probe areas of chemical space not 
represented by small molecules prepared for standard “drug-like” commercial libraries; in 
particular, they tend to have more chiral centers and more three-dimensional shape than 
compounds designed by other approaches (23, 24). 
Each of the three classes of DOS compounds represented among the 47 hits had a 
separate core structure upon which several growth-inhibitory compounds were based.  These 
compounds were not pursued further because other variations of the same core structure 
inhibited the growth of RPFWT (Figure 2.4).  The small differences between compounds that 
were specific to RPFnull and those that were not led us to hypothesize that slight differences in  
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Figure 2.2. Correlation of !-lactam activity from the chemical synthetic lethal screen with 
molecular properties.  !-lactams with activity against RPFnull did not have distinct molecular 
weights (left) or octanol/water partition ratios(right) from those with no activity.  All !-lactams 
screened are plotted; trendlines were determined by least squares linear regression. 
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Figure 2.3. Comparison of cephalosporin and penicillin hits from the chemical synthetic lethal 
screen.  The cephalosporin core structure often contains residual groups at R1 and R2 of up to 800 
Da. The cloxacillin modification of the penicillin core contains a similarly bulky group. 
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DOS Class 1 
 
 
 
 
 
 
DOS Class 2 
 
 
 
Figure 2.4 continued on next page 
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DOS Class 3 
 
 
Figure 2.4 (Continued). Representative chemical structures for synthetic lethal DOS 
compounds.  Chemical structures are displayed for each of the three DOS scaffolds showing 
activity against both specific activity against RPFnull and general activity against RPFWT and 
RPFnull.  The left compound for each class is an RPFnull-specific example compound, while the 
right compound is an example compound with activity against RPFWT. 
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chemical characteristics from side group variation might affect the relative ability of each 
compound to traverse the cell walls of RPFWT and RPFnull. 
 In particular, compounds of DOS Class 1 (Figure 2.4) were hypothesized not to have an 
RPF-specific mechanism of action because several active compounds had stereocenters with 
inverted chirality relative to the rest; since enzymes are chiral molecules, a notional enzyme 
target of DOS Class 1 would be expected to interact with only scaffolds containing one chirality.  
Furthermore, 7 out of 17 DOS Class 1 compounds displayed modest activity in an erythrocyte 
lysis assay.  Erythrocytes are eukaryotic cells lacking DNA, and consequently much enzymatic 
machinery; any compound that lyses both erythrocytes and bacteria is unlikely to act through an 
enzyme-specific mechanism.  Out of all the compounds tested in this assay, DOS Class 1 were 
the only compounds that showed any activity against erythrocytes (Figure 2.5). 
 
Macrocycles 
 Another class of compounds displaying similar behavior to DOS Class 1 were a series of 
large peptide-mimetic macrocycles (Figure 2.6).  Only two of these molecules passed the 
potency and specificity filters above, but upon inspection, it appeared that the others had failed 
because, although displaying much greater inhibition of RPFnull, they also modestly inhibited 
growth of RPFWT (Figure 2.6).  The cyclic shape and numerous hydrogen bonding opportunities 
afforded by these molecules, as well as the fact that they comprised three sets of enantiomeric 
pairs, led us to hypothesize that they acted as ionophores. 
 The macrocycles were tested in an erythrocyte lysis assay, but did not display any 
activity at screening doses, in comparison to DOS Class 1 compounds, which displayed potent,  
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Figure 2.5. Dose-response relationships for small molecules in an erythrocyte lysis assay.  Small 
molecules were subjected to an erythrocyte lysis assay over a range of concentrations.  
Erythrocyte lysis after 24 h was determined by measuring the optical density at 400 nm, which in 
this assay corresponds to the amount of hemoglobin released.  Individual compounds are not 
marked here for clarity.  Members of DOS Class 1 cause clearly elevated erythrocyte lysis at 
high concentrations. 
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Figure 2.6. Peptide-like macrocycles, a class of RPFnull-specific growth-inhibitory molecules. 
XW_SM2_11 (A), typical of the peptide-like macrocycles, displays modest RPFnull-specific 
inhibitory activity over at least one logarithm of concentrations (B).  Inhibitory activity was 
determined by measuring outgrowth by relative fluorescent units, as described in Materials and 
methods. 
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dose-dependent activity at multiple dilutions of screening concentrations (Figure 2.5).  This 
suggests that they may be acting in an MTB-specific manner rather than as ionophores. 
 
Eight-membered rings 
 Four hits were azocine derivatives (Figure 2.7) that shared an N-linked benzyl 
methyltrifluoride ether.  Eight other azocine compounds sharing the benzyl substitution did not 
show activity in either screen. 
 
Unclassified compounds 
 Several compounds showed RPF-specific activity but no structural similarities (Figure 
2.8) to other RPF-specific compounds.  Like the eight-membered rings, these compounds were 
deemed insufficiently-represented to merit the same level of interest as the other classes of hits. 
 
Slight vulnerability of RPFnull to other antibiotics 
 Finally, a parallel investigation of RPFnull noted a modest sensitization of RPFnull to the 
macrolide class of antibiotics on agar (25); our dose-response assay noted a similar phenotype in 
liquid culture (Figure 2.9).  Dose-response assays with other common antibiotics noted very 
moderate increases in RPFnull sensitivity to vancomycin and rifampin, as well as sensitivity to all 
macrolides (Table 2.3).  These changes in sensitivity were not noted in the chemical screen 
because, for RPFnull-specific activity to be detected, the screening concentration must fall within 
a very small window of specificity; many compounds, such as rifampin, were screened at 
concentrations that exceeded both the RPFnull IC90 (inhibitory concentration of 90 % of growth) 
and the higher RPFWT IC90. 
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Figure 2.7. 1-(4-trifluoromethoxy)-benzyl azocines, a class of RPFnull-specific growth inhibitory 
small molecules.  These 1-(4-trifluoromethoxy)-benzyl azocines (A), showed moderate RPFnull-
specific activity in dose-response assays (B).  Inhibitory activity was determined by measuring 
outgrowth by relative fluorescent units, as described in Materials and methods.  Two other 
azocine derivatives, not pictured, showed similar activity. 
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Figure 2.8 continued on next page 
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Figure 2.8 (Continued).  Singly-represented small molecules scaffolds with RPFnull-specific 
growth inhibitory activity.  All of these compounds (A-H) displayed RPFnull-specific activity, but 
did not have obvious structural features in common with the other hits from the screen. 
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Figure 2.9. Inhibition of RPFnull by the macrolide class of antibiotics.  The macrolides 
clarithromycin (left) and azithromycin (right) showed substantial RPFnull-specific activity, which 
could be complemented by the addition of rpfC, rpfD, and rpfE in single copy under the control 
of their native promoters.  Erythromycin, not shown, displayed similar activity, but degraded 
rapidly.  See Materials and methods, Chapter 3. 
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Table 2.3. Increases in sensitivity of RPFnull to common antibiotics. 
 
Antibiotic Fold Sensitization a 
Amikacin 1 
Cefotaxime 8 
Ciprofloxacin 1 
Clarithromycin 128 
Clofazimine 1 
Isoniazid 1 
Rifampin 2 
Vancomycin 8 
a
 A fold change of 1 indicates that there was no detectable difference between RPFnull and RPFWT. 
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Section 2.4: Conclusion 
 The most parsimonious explanation for the sensitization of RPFnull to a wide variety of 
compounds is that these compounds all preferentially inhibit RPFnull through a single 
vulnerability introduced by the deletion of the RPFs.  Two well-described classes of antibiotics, 
the cephalosporins and the macrolides, showed broad RPFnull specificity among many 
compounds within the classes, but the known mechanisms of these two classes of compounds are 
quite distinct: cephalosporins target the cell wall (26), while macrolides affect the ribosome (27). 
Furthermore, none of the compounds described in the screen for specific inhibitors of RPFnull 
show structural similarity to either the macrolides or the cephalosporins, suggesting that these 
compounds have distinct modes of inflicting cell death or bacteriostasis. 
 One candidate vulnerability through which all of these compounds may gain potency is 
the permeability of the RPFnull outer membrane.  This possibility is supported by the sensitization 
of RPFnull to sodium dodecyl sulfate (SDS) (15); in Gram negative bacteria, disruption of the 
outer membrane results in increased SDS sensitivity (28).  It is also suggested naturally by the 
covalent linkage of the RPF-regulated peptidoglycan to the inner mycolic acid leaflet of the outer 
membrane (29); from such a linkage, it follows that disruptions in the peptidoglycan may have 
effects on the mycolic acids. 
 We pursued the hypothesis that permeability was a mechanism of RPFnull sensitization to 
small molecules in the specific context of cephalosporin sensitivity in Chapter 2. 
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Section 2.5: Materials and methods 
High-throughput chemical screening 
Mycobacterium tuberculosis strain H37Rv%rpfACDEB (a generous gift of V. Mizrahi) 
was marked with a hygromycin resistance cassette-expressing vector, pUV15, containing red 
fluorescent protein under the control of the promoter for Rv3583c, a strongly, constitutively 
expressed mycobacterial gene. 
 The strains were grown at 37 °C and 2 RPM to mid-log phase (OD600 0.6 – 0.8) in 
Middlebrook 7H9 medium containing 0.2% glycerol, 0.05% Tween 80, and Middlebrook OADC 
Enrichment (Becton Dickenson #212351).  Cell clumps were removed by centrifugation at 58 
xg, and the OD600 was adjusted to 0.05.  Cells were then aliquoted into 384-well plates 
containing compounds, 20 µL per well.  The average compound concentration was ~25 µM in 
7H9 medium with an additional 0.5% dimethyl sulfoxide. 
 Cells were grown for four days at 37 °C, and then growth was assessed by measuring 
fluorescence ('ex 444 nm 'em 484 nm).  Compounds were designated as inhibitory if the mean 
growth in duplicate compound wells was less than the mean growth of control wells containing 
rifampin at a concentration at which the Z factor (15) equaled zero.  Compounds were designated 
as specifically inhibitory to RPFnull if the difference in growth between H37Rv (22) and RPFnull 
was less than the difference between DMSO controls for H37Rv and rifampin controls for 
RPFnull. 
 
Secondary assays 
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Compounds selected for follow-up were placed in 7H9 medium in 384-well plates as 
above, but at six separate two-fold dilutions below the screening concentration.  Measurement of 
growth was carried out as described for high-throughput screening.  The growth of strains 
H37Rv RPFWT, H37Rv%rpfAB, and H37Rv%rpfE was assessed by measuring the fluorescence 
resulting from pUV3583c-GFP, a constitutively active GFP reporter maintained by hygromycin, 
with 'ex 485 nm and 'em 538 nm. 
 
Erythrocyte lysis assay 
Compounds selected for follow-up were placed in 384-well plates in 20 µL phosphate-
buffered saline. 
Recently drawn whole human blood with acid-citrate-dextrose anticoagulant mixture was 
mixed with RPMI medium supplemented with fetal bovine serum.  Whole cells were collected 
by centrifugation and washed twice in the same mixture; they were finally resuspended at twice 
their original blood concentration. 
Aliquots of 20 µL whole blood cells were added to the 384-well compound plates and 
incubated at 37 °C for 24 h.  Cells were sedimented and hemoglobin release in the isolated 
supernatant was measured.  This measurement was performed by adding an equal volume of 
DIHB-250 reagent (Gentaur Molecular Products) to supernatants, incubating for 5 min, and 
measuring OD400. 
 
Dose-response curves 
 Compounds were stored at -20 °C in dimtheyl sulfoxide (DMSO).  The potency of 
compounds was determined as follows: 384-well plates were filled with 20 µL 7H9 medium and 
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100 nL DMSO per well.  Compounds were arranged in the plates in twofold dilutions from the 
highest compound concentration to the lowest. 
 MTB grown to mid-logarithmic phase (OD600 0.5 – 1.0) was centrifuged at 58 xg to 
remove clumps and then diluted in fresh 7H9 medium to OD600 0.1.  Cells were added in 20 µL 
aliquots to each well, with individual strains being measured in quadruplicate, sextuplicate, or 
octuplicate. 
 Cells were grown for 100 – 200 hr at 37 °C in sealed containers.  After incubation, 
growth was measured by OD600.  The IC90 was computationally identified for each singlicate 
dilution series as the lowest concentration at which OD600 was less than 10 % of the growth in 
the absence of drug; for combinations of strain and drug for which singlicate measurements 
yielded different results, a range was reported.  In additional to these technical duplicates, all 
strain and drug combinations were tested in at least two independent experiments.  Although 
absolute numbers differed between experiments due to variation in drug stocks, differences 
between strains remained constant. 
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Chapter 3: The cephalosporin susceptibility of a strain of 
Mycobacterium tuberculosis lacking the resuscitation-promoting 
factors results from a change in permeability 
 
Section 3.1: Abstract 
 
 The resuscitation-promoting factors of Mycobacterium tuberculosis are essential for 
survival in a mouse model of tuberculosis infection, but are dispensable for in vitro growth.  
Previously, we showed that resuscitation-promoting factors are required for wild-type tolerance 
to several antibiotics, including cephalosporins, macrolides, and vancomycin.  Here, we sought 
to investigate the mechanism by which the resuscitation-promoting factors maintain this 
tolerance.  Focusing on the case of the cephalosporins, we investigated the primary determinants 
of cephalosporin sensitivity and resistance: permeability, !-lactamase activity, and target site 
modification.  The permeability of the mycolic acid outer membrane of Mycobacterium 
tuberculosis was directly evaluated by comparing the access of extracellular substrates to the 
periplasmic !-lactamase activity; in resuscitation-promoting factor-deficient strains, this access 
was greatly increased.  The contribution of specific resuscitation-promoting factors to 
cephalosporin sensitivity was evaluated, and the results broadly supported the hypothesis that 
there exists a “functional hierarchy” of importance for these genes, in which rpfA and rpfB 
contribute to specific cellular functions, while the other resuscitation-promoting factors show 
some level of redundancy.  Together, these results indicate that the resuscitation-promoting 
factors are important for the coordination of the mycolic acid and peptidoglycan layers of the 
Mycobacterium tuberculosis cell wall.  Their function in maintaining the impermeability of the 
cell wall may contribute to their in vivo survival defect. 
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Section 3.2: Introduction 
 Previously, our laboratory performed a chemical screen for small molecules that 
specifically inhibited growth of a strain of Mycobacterium tuberculosis (MTB) lacking all five 
resuscitation-promoting factors (RPFs), H37Rv%rpfACDEB (RPFnull), but did not inhibit growth 
of wild-type MTB (RPFWT).  One of the most significant classes of hits was the cephalosporin 
class of antibiotics. 
 The cephalosporins were interesting for several reasons.  First, although they are not 
currently popular in tuberculosis chemotherapy, recent work has shown that some !-lactams, 
such as meropenem, have potent sterilizing activity against MTB.  This work focused explicitly 
on meropenem because of its low rate of hydrolysis by the MTB !-lactamase (1).  Another 
compound with a low rate of MTB !-lactamase hydrolysis is cefotaxime; its KD is in the 
millimolar range (2).  Cefotaxime is also one of the cephalosporins that acts against RPFnull with 
enhanced potency, which could potentially make it a viable candidate for therapeutic use in 
combination with an RPF inhibitor (1). 
 Beyond clinical reasons, understanding the mechanism by which RPFnull is sensitized to 
the cephalosporins presented an opportunity to learn about RPF biology.  The RPFs are thought 
to be peptidoglycan lytic transglycosylases, which cleave the !-1,4-glycosidic bond between N-
acetylglucosamine and muramic acid (3).  But little is known about the specific cellular spatial or 
temporal contexts in which individual RPFs function, and little is known about what other 
pathways may be affected by peptidoglycan !-1,4-glycosidic bond hydrolysis.  For instance, the 
peptidoglycan region in which RPFs function is covalently bound to the surrounding 
arabinogalactan and mycolic acid layers (4), which may be affected by peptidoglycan 
conformation.  The multiplicity of RPF paralogs in MTB raises further biological questions; it is 
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not clear whether they are functionally redundant or have diversified to perform separate 
functions. 
Some characteristics appear to be specific to individual RPFs.  For example, only RpfB 
and RpfE interact with RipA, a peptidoglycan endopeptidase (5).  RpfA is the only RPF under 
regulatory control by the cAMP receptor protein encoded by Rv3676 (6).  Deletion of rpfA also 
results in a notably different transcriptional response in comparison to the other RPFs (7). 
Many characteristics, however, are common to all of the RPFs.  They display a uniform 
expression pattern during growth in broth culture, with high expression in early logarithmic 
phase, gradually decreasing to undetectability in stationary phase (8).  Deletions of several 
separate RPF subsets leads to decreased survival  during host infection (9, 10, 11).  Finally, our 
work in Chapter 2 showed that deletion of both rpfE and rpfA/rpfB resulted in heightened 
sensitivity to multiple small molecules. 
 Among these small molecules, extensive research has been done concerning the 
cephalosporins subgroup.  There are three broad ways a two-membrane organism like MTB 
commonly acquires !-lactam sensitivity (12): [1] through alteration of its permeability; [2] 
through alteration of its !-lactamase activity; [3] through modification of its penicillin-binding 
proteins. 
 In this chapter, we investigate the possible contribution of each of these factors to the 
altered sensitivity of RPFnull to cephalosporins; in Chapter 4, we investigate in more detail the 
ability of modification of penicillin-binding proteins to contribute to changes in !-lactam 
sensitivity. 
 
 
 84 
Section 3.3: Results and discussion 
**In Chapter 2, we identified 18 !-lactams with RPFnull-specific inhibitory activity; nine 
were selected among the 47 most potent compounds from a screen for RPFnull-specific growth 
inhibitory compounds.  These  were the penicillin dicloxacillin and the cephalosporins cefazolin, 
cefotaxime, cefditoren, ceftriaxone, cefmetazole, cefoperazone, cephaloridine, and cephapirin.  
Cefotaxime was selected for more intensive investigation.  The IC90 (the concentration at which 
90 % of growth was inhibited) for RPFnull against cefotaxime was ~8-fold lower than in RPFWT 
(Table 3.1), consistent with our screening results.  We observed similar sensitization of the 
mutant for ceftriaxone and cefamandole.  Colony-forming unit (CFU) measurement for RPFWT 
and RPFnull verified that observed effects on OD600 arose from bactericidal activity (Figure 3.1). 
To determine which RPFs contributed to RPFnull’s increased !-lactam sensitivity, we 
measured the cefotaxime IC90 against a range of mutants lacking one or more RPFs (Table 3.1).  
No individual RPF gene was singlehandedly responsible for RPFWT-level cefotaxime resistance.  
The biggest increases in sensitivity came with the loss of rpfA and rpfB.  In general, with the 
progressive loss of RPFs, cefotaxime sensitivity gradually increased.    The additive effects 
observed suggest functional redundancy of the RPFs.  Restoration of rpfC, rpfD, and rpfE by 
integration of a plasmid carrying these genes at the mycobacteriophage L5 attB site suppressed 
cefotaxime sensitivity in RPFnull.** 
This complementation of RPFnull strongly suggested that cefotaxime sensitivity was a 
result of the RPF deletions, not any secondary genomic mutations acquired during the generation 
of RPFnull.  Target site modification, which is the alteration of the !-lactam binding site on a 
penicillin-binding protein to change its affinity for !-lactams, most often occurs through genetic 
mutation of the penicillin-binding protein gene (12).  In addition to our complementation of 
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Table 3.1. IC90s of RPFnull and related strains to cephalosporins. 
 
!-Lactam Straina       IC90 (µM)b
 
Cefotaxime H37Rv (RPFWT) 26 
 H37Rv%rpfA 13-26 
 H37Rv%rpfB 13-26 
 H37Rv%rpfC 26 
 H37Rv%rpfD 26 
 H37Rv%rpfE 26-52 
 H37Rv%rpfAB 26 
 H37Rv%rpfACBED::pHrpfCDE 6.5-26 
 H37Rv%rpfACBE 6.5 
 H37Rv%rpfACBED (RPFnull) 1.6-3.3 
 H37Rv%rpfACDEB 0.78 
Cefamandole H37Rv 390-780 
 H37Rv%rpfACDEB 98 
   With potassium clavulanate (1 µM) H37Rv 24 
 H37Rv%rpfACDEB 1.5 
Ceftriaxone H37Rv 3.2-6.3 
 H37Rv%rpfACDEB 1.6 
a
 From (7, 10, 11). 
b
 Differences in IC90s are representative of at least two independent experiments containing at least four duplicates each; for 
cefamandole, amounts of clavulanate were varied across duplicates. 
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Figure 3.1. RPFWT and RPFnull were grown in 3 µM cefotaxime and surviving bacteria were 
enumerated at the indicated time points by plating for colony-forming units on 7H10 agar.  The 
result shown is representative of the experiment performed in triplicate.  Error bars for duplicates 
are drawn, but may not be apparent due to precision. 
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RPFnull, we performed whole-genome sequencing to identify any possible confounding 
secondary mutations.  We detected no mutations in any of MTB’s penicillin-binding proteins.  
This strongly suggested that target site modification was not the means by which RPFnull had 
become sensitized to cefotaxime, so we turned our attention to changes in the MTB !-lactamase. 
**To test whether increased !-lactam sensitivity in RPFnull could be due to loss of !-
lactamase activity with sequential deletion of the RPFs, we measured the cefamandole IC90 of 
RPFWT and RPFnull in the presence of 1 µM clavulanate, a !-lactamase inhibitor.  If differences in 
!-lactamase activity account for the differences in cephalosporin sensitivity in the two strains, its 
inhibition by clavulanate should cause the cefamandole IC90 values for RPFWT and RPFnull to 
converge.  In fact, treatment with clavulanate did not cause this convergence; instead, a small 
divergence was observed (Table 3.1), thus demonstrating that loss of !-lactamase activity does 
not account for the increased !-lactam sensitivity in RPFnull. 
Since RPFnull is also hypersensitive to SDS and macrolide antibiotics relative to RPFWT, 
we hypothesized that it may have a general permeability defect underlying both these phenotypes 
as well as cephalosporin sensitivity.  To test this, using previously reported methods (13), we 
measured the relative rates of cefamandole hydrolysis by intact RPFWT and RPFnull cells (Figure 
3.2).  When these rates are normalized to their respective rate of hydrolysis in lysates, they 
provide a comparison of the relative rates of diffusion across the intact outer membrane; in 
effect, this provides a measure of relative permeabilities, provided that the concentration of 
cefamandole internal to the permeability barrier is below the order of the !-lactamase Km.  In 
highly permeable cells, intracellular hydrolysis of cefamandole is assumed to be rate-determining 
while in poorly permeable cells, diffusion through the permeability barrier is assumed to be rate-
limiting. 
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Figure 3.2. Kinetics of cefamandole hydrolysis. Absorption at 285 nm of H37Rv (") or 
H37RvΔrpfACDEB (#). Samples were mechanically lysed (A) or resuspended in phosphate-
buffered saline intact (B) and exposed to 20 mM cefamandole nafate. Subsequently, absorption 
measurements were taken at the indicated times. The illustrated values are averages of two 
technical replicates for each strain. Parameters vlysed and vintact are the slope and error calculated 
from the aggregated data for each strain. 
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We calculated a vintact/vlysed ratio of 1.09 +/- 0.04 for RPFnull, compared to an RPFWT 
vintact/vlysed ratio of 0.07 +/- 0.09.  We also found that the loss of cefamandole sensitivity 
observed with the restoration of rpfC, rpfD, and rpfE in RPFnull was reflected in a 
correspondingly lower vintact/vlysed ratio of 0.19 +/- 0.04, indicative of decreased permeability.  
These results show that RPFnull has increased permeability to cefamandole. 
We have found that the deletion of RPFs in M. tuberculosis H37Rv strain results in 
increased sensitivity to cephalosporins because of a resulting increased permeability in its outer 
membrane.  While this work provides a clear demonstration of the change in permeability with 
respect to cephalosporins, it is possible that the reported sensitivity of RPFnull to other small 
molecules, including SDS (11), the macrolide class of antibiotics, vancomycin, and rifampin (14) 
may also be due to this same permeability defect.  This finding suggests that changes in 
mycobacterial cell physiology at the peptidoglycan level may have far-reaching effects on the 
essential mycolic acid permeability barrier and that such alterations may affect the ability of the 
mutant bacilli to survive in vivo.  Specifically, loss of particular cell wall-modifying enzymes 
may decouple the rates of peptidoglycan and outer membrane synthesis, as suggested in a model 
by Heidrich et al. (15) thus causing defects in the outer membrane that permit a wide range of 
molecules to diffuse in and out of the cell. 
Our work shows that genetic ablation of RPF activity can potentiate a number of small 
molecules against mycobacteria, including known antibiotics presently unused in therapy.  The 
use of RPF inhibitors should have similar effects.  Recently, Demina et al. (16) have identified 
several small molecules with promising RPF inhibitory activity, while more generally, bulgecin 
is a known inhibitor of lytic transglycosylases. !-lactams are historically one of the most 
successful antibiotic classes, and the use of the !-lactamase inhibitor clavulanate to potentiate 
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them against mycobacteria has recently been proposed (1).  This work provides a mechanistically 
orthogonal approach to potentiating !-lactam antibiotics, and other antibiotics.** 
 
Section 3.4: Materials and methods 
Strains and growth conditions 
 Mycobacterium tuberculosis H37Rv and its derivatives were grown to mid-logarithmic 
phase at 37 °C in 30 mL sterile square containers; culture aeration was maintained by shaking at 
100 RPM with a constant head space of 20 mL. 
 The growth medium was Middlebrook 7H9 Broth supplemented with Middlebrook 
OADC Enrichment (Becton Dickenson #212351), 0.2 % glycerol, and 0.05 % Tween 80. 
 
Complementation 
 The genes rpfC, rpfD, and rpfE were introduced to RPFnull on the plasmid pHINT under 
the control of their native promoters (construct a generous gift of V. Mizrahi): RPFnull was grown 
to logarithmic phase (OD600 0.6 – 1.0) and then pelleted at 2,850 xg for 10 min.  Cells were 
washed three times in 10 % glycerol, 0.05 % Tween 80 at 37 °C and then resuspended in the 
same solution at 1/20 the original volume.  The pHINT construct, 1 µg, was transformed into 400 
µL cells in a 1 mm electroporation cuvette.  This mixture was electroporated at 2,500 V, 1,000 
(, 4 µF.  The cells were allowed to recover for 24 h in 5 mL 7H9 medium in the growth 
conditions described above.  Colonies were isolated after growth on 7H10 agar medium 
supplemented with Middlebrook OADC Enrichment, 0.5 % glycerol, and 0.05 % Tween 80. 
 
Permeability assay 
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 Cells were grown to mid-logarithmic phase, OD600 0.6 – 1.0.  To measure vintact, cells 
were pelleted by centrifugation at 2,850 x g and resuspended at 20x their original concentration.  
Cells were mixed in a 9:1 ratio with a prepared stock of 10 mg/mL cefamandole nafate in 
phosphate-buffered saline.  Cefamandole concentration was monitored by the absorbance at 285 
nm, which formed a characteristic peak centered at this wavelength in 7H9 medium or 
phosphate-buffered saline.  For data collection, cell-drug mixtures were vigorously mixed, and 
then 100 µL aliquots were withdrawn at 5 – 15 min intervals, centrifuged at 16,100 x g for 2 min 
to remove debris, transferred to 96-well plates and read by a SpectraMax plate reader (Molecular 
Devices).  A rate was determined from the linear least squares regression, calculated by 
Microsoft Excel. 
 The vlysed parameter was calculated like vintact, except cells were resuspended at 10x 
instead of 20x their original concentration in 7H9 medium, not phosphate-buffered saline.  
Mechanical lysis was performed using a beadbeater (BioSpec): 0.5 mL 0.1 mm zirconia/silica 
beads and 1 mL cells were beaten at maximum speed in a 1.5 mL conical microfuge tube in 6x 
30 s pulses. 
 
Dose-response curves 
 Compounds were stored at -20 °C in dimtheyl sulfoxide (DMSO) or -80 °C in 7H9 
medium.  The potency of compounds was determined as follows: 384-well or 96-well plates 
were filled with 20 µL 7H9 medium per well; if a compound in a DMSO stock was being tested 
384-well (96-well) plates were filled with 20 µL (90 µL) 7H9 medium and 1 % or 2 % DMSO.  
Compounds were arranged in the plates in twofold dilutions from the highest compound 
concentration to the lowest. 
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 MTB grown to mid-logarithmic phase (OD600 0.5 – 1.0) was centrifuged at 58 x g to 
remove clumps and then diluted in fresh 7H9 medium to OD600 0.1.  Cells were added in 20 µL 
(10 µL) aliquots to each well, with individual strains being measured in quadruplicate, 
sextuplicate, or octuplicate. 
 Cells were grown for 100 – 200 hr at 37 °C in sealed containers.  After incubation, 
growth was measured by OD600.  The IC90 was computationally identified for each singlicate 
dilution series as the lowest concentration at which OD600 was less than 10 % of the growth in 
the absence of drug; for combinations of strain and drug for which singlicate measurements 
yielded different results, a range was reported.  In additional to these technical duplicates, all 
strain and drug combinations were tested in at least two independent experiments.  Although 
absolute numbers differed between experiments due to variation in drug stocks, differences 
between strains remained constant. 
 
Whole-genome sequencing 
 Genomic DNA was prepared from RPFnull as follows: cells were spun at 2,850 x g and 
resuspended in 1 mL of the supernatant.  They were heated to 100 °C for 15 min.  The cells were 
spun at 2,100 x g 20 min and resuspended in 0.95 mL bug lysis solution: 25 mM Tris pH 7.9, 10 
mM EDTA, 0.9 % dextrose.  The cells were spun at 16,100 x g 10 min, then resuspended in 0.5 
mL bug lysis solution containing 1 mg/mL lysozyme.  Cells were incubated at 37 °C 20 h.  100 
µL 10% SDS was used to terminate the reaction and 50 µL Proteinase K (New England BioLabs 
P8102) was added.  This mixture was heated to 55 °C for 20 min.  200 µL 5 M NaCl was added.  
To this mixture, 160 µL cetrimide solution was added: 4.1 % NaCl, 10 % cetrimide.  This 
mixture was heated to 65 °C 10 min.  DNA was extracted with 1 mL 24:1 chloroform:isoamyl 
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alochol.  Phase separation was achieved with centrifugation at 16,100 x g 5 min; the extraction 
was repeated.  800 µL aqueous phase was extracted and mixed with 560 µL 2-propanol.  This 
was incubated at room temperature for 5 min and then spun at 16,100 x g 5 min.  The 
supernatant was aspirated and 1 mL 70 % ethanol added, followed by mixing by inversion.  This 
mixture was spun at 16,100 x g 5 min and then air-dried.  DNA was resuspended in 50 µL TE pH 
7.8.   Whole-genome sequencing was performed by the Broad Institute using Illumina 
technology with 36 bp reads.  Alignment and screening for mutations were performed using the 
VAAL algorithm (17). 
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Chapter 4: PonA2 is required for mycobacterial 
cephalosporin sensitivity and carbapenem resistance 
 
Section 4.1: Abstract 
 
Recent studies have renewed interest in the !-lactam class of antibiotics as a potential 
treatment for Mycobacterium tuberculosis infection.  To understand the potential opportunities 
and limitations of this approach, we sought to identify the specific transpeptidase targets of the 
!-lactams in M. tuberculosis.  We isolated spontaneous !-lactam-resistant mutants and identified 
causative mutations in the penicillin-binding protein ponA2.  In contrast to many penicillin-
binding protein mutations, these mutations were recessive and occurred in both the 
transpeptidase target domain of the gene and the separate glycosyltransferase domain.  To 
examine ponA2 function more closely, we created a ponA2null strain.  This strain was also 
cephalosporin-resistant, but it was sensitized to carbapenems and had no phenotype with respect 
to penicillins.  Since loss of function is an unusual mechanism of !-lactam resistance, we 
wondered whether other M. tuberculosis penicillin-binding proteins could also confer resistance 
through loss of function.  Null mutations in other penicillin-binding proteins did not confer 
resistance to cephalosporins or carbapenems.  We propose to explain the unusual behavior of the 
ponA2 mutants with a model wherein ponA2 transpeptidation is replaced by the activity of an 
alternate transpeptidase in a ponA2null mutant.  The different affinities of PonA2 and the alternate 
transpeptidase would account for the altered susceptibilities to the various classes of !-lactam. 
 
Section 4.2: Introduction 
Tuberculosis is a global threat that causes 1.4 million deaths per year (1).  The causative 
organism, Mycobacterium tuberculosis (MTB), has developed concurrent resistance to every 
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first- and second-line antibiotic used against it (2); more common multidrug resistance to a 
subset of these antibiotics is spreading and probably exists in nearly every country (1).  The 
scientific community’s ongoing interest in applying antibiotics currently not used in tuberculosis 
treatment, such as !-lactams, has therefore acquired a new urgency (3, 4).  !-lactams are 
currently used only rarely in the clinic because of MTB’s high intrinsic tolerance to them (5), but 
recent work has shown that combination therapy with the !-lactamase inhibitor clavulanate may 
make several !-lactams viable treatment options (6). 
Of particular importance in developing effective therapeutic regimens for any drug is an 
understanding of how the drug acts and by what means the target pathogen may become resistant 
to treatment.  In the case of the !-lactams, it has long been understood that the antibiotic acts by 
forming a long-lived acyl-enzyme intermediate at the catalytic serine of its target, a penicillin-
binding protein (PBP), thus obstructing its activity and the resultant impact on bacterial viability 
(7). 
Bacteria usually possess several paralogous PBPs.  These PBPs are thought to be 
collectively essential enzymes responsible for synthesizing the peptidoglycan sacculus that 
encases the bacterium and opposes the turgor pressure resulting from the osmotic differential 
between the bacterial cytoplasm and the extracellular milieu (8).  The PBPs have two primary 
synthetic functions.  The first is a glycosyltransferase function, wherein they processively 
polymerize the individual subunits of peptidoglycan, called disaccharide pentapeptide, into long 
glycan strands.  The second is a transpeptidase function, wherein they crosslink pentapeptide 
from neighboring strands to form the final, netlike peptidoglycan sacculus.  The !-lactams mimic 
the substrate of the transpeptidase crosslinking domain.  The inhibition of the transpeptidase 
crosslinking function leads to a weakened sacculus.  There is some debate about the exact 
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process by which the weakened sacculus resulting from !-lactam treatment leads to bacterial cell 
death, but in the simplest model, the weakened sacculus cannot withstand the turgor pressure 
resulting from the osmotic differential between the bacterial cytoplasm and the extracellular 
milieu, and the result is an explosive release of the cytoplasmic contents (8, 9, 10). 
A precise understanding of the mechanism of bacterial cell death requires the 
identification of the particular PBPs that, when inhibited, lead to bacterial cell death.  Since not 
all PBPs are essential, !-lactams probably need inhibit a subset of them to be effective.  
Similarly, resistance can arise from any mutation that alters the affinity of some member of this 
subset of PBPs, regardless of the inhibition of the other PBPs; therefore, resistance is dominant. 
The PBP paralogs of a given species divide into several conserved functional classes.  
These include [1] bifunctional Class A high-molecular weight (HMW) PBPs, which possess both 
glycosyltransferase and transpeptidase activities; [2] Class B HMW PBPs, possessing only 
transpeptidase activities; and [3] both low-molecular weight (LMW) carboxypeptidases and 
endopeptidases, which hydrolyze rather than form peptide bonds (11).  [4] Recently, researchers 
have identified a fourth class of proteins that act on a different catalytic site in the disaccharide 
pentapeptide; the different stereochemistry at this site has led them to be termed L,D-
transpeptidases, while typical PBPs are D,D-transpeptidases (12). 
The simplest models of !-lactam killing suppose that PBP activities are inhibited, and so 
the subset of PBPs that are bound by a particular !-lactam, must be essential.  In MTB and 
related species, transposon mutagenesis experiments indicate that LMW PBPs and L,D-
transpeptidases are non-essential (13).  One Class B PBP is essential, while deletion of pairs of 
the other class A and B HMW PBPs results in severe growth and morphological defects.  This 
genetic evidence therefore suggests that these PBPs may be the !-lactam targets in MTB.  
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Indeed, Class A and B HMW PBPs are generally hypothesized to be the critical !-lactam targets 
in most bacterial species.  Nonetheless, even within the Class A and B HMW PBPs, it is not 
clear whether all of the transpeptidase domains must be inhibited by !-lactams for cell death to 
ensue, or whether only a subset of them form the molecular target. 
  !-lactam resistance in MTB is not well-studied because of the current lack of !-lactam 
use in the clinic.  In other species, !-lactam resistance sometimes occurs by target site 
modification; target site modification is an alteration in the binding site of the target protein that 
lowers its affinity for the antibiotic that inhibits it.  Resistance to !-lactams by target site 
modification typically occurs in the Class A and B HMW PBPs (8), providing further evidence 
that these classes contain the targets of the !-lactams. 
This picture is complicated by the fact that in MTB in particular, there is increasing 
appreciation of the importance of the L,D-transpeptidases.  These enzymes catalyze the 
crosslinking of amino acids at the third amino acid of nearby peptidoglycan monomers, creating 
3!3 crosslinks; in contrast, PBPs catalyze the crosslinking of the fourth amino acid of one 
monomer to the third amino acid of another, creating a 4!3 crosslinks (11).  MTB and 
Myocbacterium abscessus, a closely related strain, have both recently been shown to possess 
primarily 3!3 rather than 4!3 crosslinks (14, 15).  The relative importance of D,D- and L,D-
transpeptidases in these species may therefore differ from their relative importance in other 
bacterial species. 
Meropenem, a member of the carbapenem subclass of !-lactams, has recently been 
shown to form in vitro adducts with an MTB L,D-transpeptidase, encoded by the gene Rv0116c 
(14).  In Enterococcus faecium, the PBP 4!3 crosslinking pathway can be completely bypassed 
by 3!3 crosslinking (16).  Even in this situation, meropenem retains activity, suggesting it can 
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act by inhibition of L,D-transpeptidases.  In MTB, meropenem is effective against even cells that 
are not actively growing; stationary phase MTB is rich in 3!3 crosslinks (14).  Meropenem’s 
effectiveness against nongrowing MTB may therefore be a result if its ability to inhibit these 
L,D-transpeptidation as well as or instead of PBPs (17). 
In the work that proposed meropenem as a promising antitubercular therapeutic agent, it 
was initially selected for study because of its low affinity for the MTB !-lactamase (6).  The 
same researchers identified several cephalosporins that showed similarly low affinity but were 
not pursued (18).  We set out to investigate the !-lactam targets in MTB using the simpler case 
of these cephalosporins.  The cephalosporins are simpler because they show much lower affinity 
for L,D-transpeptidases, and so probably act by inhibition of Class A and B HMW PBPs.  We 
sought to identify HMW PBPs important for cephalosporin resistance; we hoped that these PBPs 
might be the targets of cephalosporins leading to !-lactam mediated killing. 
 
Section 4.3: Results 
Isolation of Cefotaxime-Resistant Mutants 
We wished to identify the cephalosporin resistance-determining PBP in MTB.  The 
strategy we selected was to isolate spontaneously cefotaxime-resistant mutants; in previous 
experiments in our lab (19), cefotaxime had worked well as a model cephalosporin, providing 
changes in antibiotic resistance that correlated with changes in other cephalosporins, including 
ceftriaxone, cefamandole, and cefmetazole.  We hypothesized that some spontaneously 
cefotaxime-resistant mutants would contain target site modifications in the PBP most capable of 
functioning in the presence of cefotaxime.  We made multiple attempts to generate spontaneous 
mutations in wild-type H37Rv, but no resulting strain showed reproducible resistance in liquid 
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culture.  This difficulty may result from the fact H37Rv was able to grow – with significant 
delays – at concentrations of cefotaxime very close to the solubility limit.  It may also result from 
antibiotic degradation over the long timespan required to form colonies (3-4 weeks). 
Instead of generating resistant clones from H37Rv, we generated cefotaxime-resistant 
clones by plating logarithmically growing H37Rv#rpfACDEB on 7H10 plates containing 
cefotaxime.  H37Rv!rpfACDEB is a strain of M. tuberculosis in which the five resuscitation-
promoting factors, rpfA-E, were sequentially deleted.  In a previous study, it was shown to have a 
tenfold increased sensitivity to several !-lactam antibiotics (19). 
We isolated seven independent cefotaxime-resistant colonies from H37Rv!rpfACDEB.  
We performed whole-genome sequencing to identify mutations in two of them.  Both strains 
contained single mutations in the Rv3682 gene, designated ponA2 (Figure 4.1, Table 4.1, Table 
4.2), which encodes one of two bifunctional PBPs in MTB.  No other polymorphisms were 
identified that were not also present in the parent H37Rv!rpfACDEB  strain.  We sequenced the 
ponA2 gene in the remaining, unsequenced cefotaxime-resistant strains and identified single-
nucleotide ponA2 polymorphisms in each strain (Figure 4.1).  Unexpectedly, the range of 
mutations spanned both the glycosyltransferase and transpeptidase domains of PonA2; in other 
species, mutations linked to resistance typically occur only in the transpeptidase domain, which 
is the site of !-lactam binding and inhibition (8, 11).  All of the mutations were non-synonymous 
single-nucleotide polymorphisms, and many caused changes within amino acid families, such as 
alanine to valine (Figure 4.1). 
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Figure 4.1. PonA2 is an 810 amino acid protein containing a transmembrane helix (TM), a 
glycosyltransferase domain (TG, PF00912), a transpeptidase domain (TP, PF00905), and a 
penicillin-binding protein and serine/threonine kinase-associated domain (P, PF03793).  Above 
the diagram are indicated the catalytic residues associated with the TG and TP domains.  Below 
the diagram are indicated the amino acid changes resulting from spontaneous mutations 
conferring cefotaxime resistance. 
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Table 4.1. Strains used in this work. 
 
Name Description Source 
H37Rv Laboratory strain virulent Mycobacterium tuberculosis E Rubin 
H37Rv pREC H37Rv with an acetonitrile-inducible plasmid for assisted homologous    recombination this work, (20) 
H37Rv WT H37Rv pREC after undergoing sucrose selection to lose pREC this work 
H37Rv%ponA2 H37Rv pREC marked with a hygromycin resistance cassette and after    undergoing sucrose selection to lose pREC this work 
H37Rv ponA2::Tn H37Rv containing a transposon at amino acid 737 in ponA2 (coordinate    4124127) E Rubin 
H37RvΔrpfACDEB H37Rv deleted for the genes rpfA, rpfB, rpfC, rpfD, and rpfE (21) 
ponA2R81G Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2A96V Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2D112E Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2A150V Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2T383N Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2W443S Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2C444S Spontaneous mutation of H37RvΔrpfACDEB isolated on cefotaxime. this work 
ponA2R81G:: 
   ponA2WT 
ponA2R81G with ponA2 under the control of its native promoter on pMV306- 
   G2, a single-copy integrating plasmid this work 
ponA2A96V:: 
   ponA2WT 
ponA2A96V with ponA2 under the control of its native promoter on pMV306- 
   G2, a single-copy integrating plasmid this work 
ponA2W443S:: 
   ponA2WT 
ponA2W443S with ponA2 under the control of its native promoter on 
   pMV306-G2, a single-copy integrating plasmid this work 
ponA2C444S:: 
   ponA2WT 
ponA2C444S with ponA2 under the control of its native promoter on  
   pMV306-G2, a single-copy integrating plasmid this work 
H37Rv%ponA2:: 
   ponA2WT 
H37Rv%ponA2 with ponA2 under the control of its native promoter on  
   pMV306-G2, a single-copy integrating plasmid this work 
H37Rv%ponA2:: 
   ponA2A96V 
H37Rv%ponA2 with the ponA2A96V allele under the control of its native  
   promoter on pMV306-G2, a single-copy integrating plasmid this work 
H37Rv%ponA2:: 
   ponA2C444S 
H37Rv%ponA2 with the ponA2C444S allele under the control of its native  
   promoter on pMV306-G2, a single-copy integrating plasmid this work 
H37Rv%ponA2:: 
   ponA2E100Q 
H37Rv%ponA2 with the ponA2E100Q allele under the control of its native  
   promoter on pMV306-G2, a single-copy integrating plasmid this work 
H37Rv%ponA2:: 
   ponA2S398A 
H37Rv%ponA2 with the ponA2S398A allele under the control of its native  
   promoter on pMV306-G2, a single-copy integrating plasmid this work 
H37Rv pUVi- 
   ponA2 
H37Rv with an additional copy of ponA2 under the control of a strong  
   inducible promoter on pUV15tet, a multicopy episomal plasmid this work 
H37Rv pUVi- 
   ponA2W443S 
H37Rv with the ponA2W443S allele under the control of a strong inducible  
   promoter on pUV15tet, a multicopy episomal plasmid this work 
14:C9 pUVi- 
   ponA2 
14:C9 with ponA2 under the control of a strong inducible promoter on  
   pUV15tet, a multicopy episomal plasmid this work 
14:C9 pUVi- 
   ponA2W443S 
H37Rv ponA2::Tn with the ponA2W443S allele under the control of a strong  
   inducible promoter on pUV15tet, a multicopy episomal plasmid this work 
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Table 4.2. IC90s of H37Rv and daughter strains to cephalosporins. 
 
Parent Strain IC90a
 
H37Rv%rpfACDEB parent 1 
 ponA2 R81G 2 
 ponA2 A96V 2 
 ponA2 D112E 4 
 ponA2 A150V 4 
 ponA2 T383N n.d. 
 ponA2 W443S 8 
 ponA2 C444S 8 
 ponA2 C444S + pMV306 ponA2 WT 1 
H37Rv wild-type pUV15tet GFPc 1 
 pUV15tet ponA2 wild-type 4 
 pUV15tet ponA2 W443S 2 
H37Rv ponA2::Tnd pUV15tet GFP 1 
 pUV15tet ponA2 wild-type 4 
 pUV15tet ponA2 W443S 2 
H37Rv%ponA2 parent 1 
 pMV306 ponA2 WT 0.125 
 pMV306 ponA2 A96V 0.25 
 pMV306 ponA2 C444S 0.5 
 pMV306 ponA2 E100Q 1 
 pMV306 ponA2 S398A 1 
a
 IC90s are expressed in multiples of the parent strain resistance. 
b The IC90 for this strain was not determined. 
c
 The plasmid pUV15tet is a multicopy plasmid containing ponA2 under the control of an inducible promoter.  See Materials and 
methods. 
d This strain contains a transposon insertion near the C-terminus of ponA2.  These assays were performed in the presence of 96 
µg/mL potassium clavulanate. 
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Complementation of ponA2 mutations 
Dose-response curves showed that the mutations in ponA2 were associated with varying 
modest levels of resistance; most strains were able to grow at cefotaxime concentrations from 2- 
to 10-fold greater than the parent strain (Table 4.2).  To confirm that these mutations caused the 
observed cefotaxime resistance, the W443S allele was cloned and expressed episomally in 
H37Rv under the control of several promoters.  Under heterologous promoters of various 
strengths, PonA2W443S failed to confer resistance to cefotaxime in dose-response assays (data not 
shown). 
Resistance arising from target site modification is usually dominant (8), so the inability of 
ponA2 mutant alleles to confer resistance in a merodiploid context was puzzling.  Together, the 
numerous experiments failing to show resistance arising from the mutant allele in the presence of 
the wild-type allele implied either that the mutant allele was not being expressed or that it was 
recessive.  To test the hypothesis that the ponA2 mutations were recessive, the wild-type allele 
was introduced into one of the originally isolated mutants, PonA2C444S, in single copy under the 
control of its native promoter.  The resulting strain lost all resistance associated with the 
PonA2C444S genotype (Figure 4.2, Table 4.2), confirming that the PonA2C444S mutation caused 
resistance and that it was recessive. 
 
Deletion of ponA2 leads to cefotaxime resistance 
We wished to test whether these unusual recessive !-lactam resistance mutations could 
confer resistance in MTB H37Rv, or whether their resistance depended on the 
H37Rv#rpfACDEB background in which they had originally been identified.  Since the 
mutations were recessive, simply expressing them in H37Rv in trans and testing resistance  
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Figure 4.2. Sensitivity conferred by ponA2 alleles of Mycobacterium tuberculosis.  In the 
background H37Rv%rpfACDEB (upper left), resistance conferred by the C444S allele can be 
suppressed by addition of the wild-type allele (WT) under the control of its native promoter on a 
single-copy integrating plasmid.  The null allele confers resistance to cefotaxime (upper right), 
sensitivity to meropenem (lower right), and has no effect on cloxacillin susceptibility (lower 
left). 
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would not work.  Instead, H37Rv%ponA2, containing a clean deletion of ponA2, was created.  
The complete loss of ponA2 from H37Rv actually conferred an even higher level of resistance 
than the ponA2C444S allele had conferred in H37Rv#rpfACDEB (Figure 4.2, Table 4.2).  
Previously, decreased ceftriaxone susceptibility has been observed in Mycobacterium smegmatis 
deleted for ponA2 (22), but the same laboratory showed that ponA2 disruption in MTB actually 
increased susceptibility to !-lactams (23).  These results may be explained by the unusual dose-
response relationship for H37Rv%ponA2 (Figure 4.2).  Although the concentrations of 
cefotaxime at which H37Rv%ponA2 can grow are substantially higher than its parent, 
H37Rv%ponA2’s growth rate at these high levels was very slow.  Furthermore, at levels of 
cefotaxime well below the wild-type inhibitory concentration, H37Rv%ponA2 continued to 
display slower growth than in the absence of drug (Figure 4.2).  The effect at low levels of drug, 
while modest, was reproducible in many independent assays. 
Complementation of H37Rv%ponA2 with ponA2WT under the control of its native 
promoter suppressed the new resistance phenotype completely, restoring the wild-type growth 
pattern (Table 4.2).  In contrast, the ponA2A96V allele, which had had one of the lowest 
susceptibilities among the resistant mutants, only partially suppressed the resistance of 
H37Rv%ponA2; this was consistent with the low level of resistance conferred by this allele in 
H37Rv%rpfACDEB (Table 4.2).  The intermediate phenotype of ponA2A96V between ponA2null 
and ponA2WT led us to the hypothesis that the ponA2 SNPs may provide resistance through 
partial loss-of-function, in contrast to the greater resistance phenotype displayed by the ponA2null 
complete loss of function allele.  This would be consistent with the recessive behavior of the 
SNPs, which is otherwise inexplicable by the well-described !-lactam resistance mechanisms. 
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Mutations in PonA2 confer cefotaxime resistance by partial loss of function 
Previously, it has been shown that disruption of ponA2 by transposon mutagenesis 
confers hypersensitivity to heat stress, lysozyme, and sodium dodecyl sulfate (24).  These 
phenotypes were only investigated in a transposon mutant, and so it is not certain which PonA2 
domains they depend on; rather, they provide a functional test for the presence of PonA2.  We 
were curious whether our ponA2 SNPs, which appear to confer PonA2 loss of function vis-à-vis 
cefotaxime resistance, also cause loss of function in whichever PonA2 domain is responsible for 
these other phenotypes. 
We expressed the ponA2WT, ponA2A96V, and ponA2C444S alleles under the control of their 
native promoter in H37Rv%ponA2.  The ponA2A96V and ponA2C444S alleles represent mutations 
from the glycosyltransferase and transpeptidase domains, respectively.  The mutant alleles 
conferred significantly increased sensitivity to 24 h of incubation at 45 °C compared to ponA2WT 
(Figure 4.3).  The relative sensitization conferred by the ponA2A96V and ponA2C444S alleles in 
comparison to ponA2WT was comparable to that seen for PonA2 loss of function in previous 
assays (24).  This result provides functional evidence that the ponA2 SNPs and ponA2 loss of 
function-mediated cefotaxime resistance arise from the same biological role of PonA2 as its heat 
stress phenotype. 
 
PonA2 transpeptidase activity is essential for cefotaxime sensitivity and heat stress 
tolerance 
PonA2 has two catalytic activities, a glycosyltransferase activity for glycan chain 
polymerization, and a transpeptidase activity for peptide crosslinking (11).  Its paralog PonA1 
has both of these catalytic activities (11) and plays a structural role, physically interacting with  
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Figure 4.3. Surival of Mycobacterium tuberculosis ponA2 mutants following heat stress.  
H37Rv%ponA2 was subjected to incubation at 45 C for 24 h.  Colony-forming units in 
suspension were enumerated before and after incubation, and a percent survival was calculated.  
A96V is a mutation in the ponA2 glycosyltransferase domain, while C444S is a mutation in the 
transpeptidase domain.  E100Q and S398A are mutations at the active sites in the 
glycosyltransferase and transpeptidase domains, respectively. 
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and contributing to the activity of the endopeptidase RipA (25).  Therefore, beyond its catalytic 
roles, PonA2 may also play a structural role or contribute to an additional function with its 
PASTA domain (Figure 4.1), about which relatively little is known. 
To understand better which domain or feature of PonA2 is responsible for making H37Rv 
sensitive to cefotaxime, we constructed by site-directed mutagenesis a ponA2S398A allele.  S398 
contains the active nucleophilic hydroxyl moiety responsible for forming an acyl-enzyme 
intermediate in PonA2-mediated transpeptidation, or peptidoglycan crosslink formation (11).  
This mutant, expressed under the control of the native promoter, failed to complement the 
cefotaxime hypersensitivity phenotype of H37Rv%ponA2, while the wild-type allele expressed 
on the same vector completely restored sensitivity.  Furthermore, the transpeptidation mutant 
showed the same heat stress hypersensitivity phenotype that the ponA2null and ponA2 single-
nucleotide polymorphic alleles showed, indicating that PonA2 transpeptidation is essential for 
heat stress tolerance as well (Table 4.2, Table 4.3, Figure 4.3). 
 The catalytically inactive glycosyltransferase mutation, ponA2E100Q, showed the same 
heat stress and cefotaxime susceptibility phenotypes as ponA2S398A, but this result was expected, 
because the transpeptidase activity of bifunctional PBPs is believed to be glycosyltransferase-
dependent (26).  In other words, the inactivation of glycosyltransferase activity also inactivates 
transpeptidase activity. 
 All together, then, these results show that ponA2 plays a key role in the molecular events 
following exposure of MTB to !-lactams.  Its presence renders MTB vulnerable to !-lactam 
exposure, and this vulnerability depends on the catalytic transpeptidase activity of PonA2.  The 
probable reason for vulnerability, then is the covalent inactivation of the PonA2 transpeptidase  
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Table 4.3. Susceptibility of PBP loss of function mutants to !-lactams. 
 
PBP Disrupted cloxacillina cefotaximea cephalexina meropenema 
none - - - - 
PbpA S S S S 
Rv2864c product - - - - 
PonA1 n.d. - n.d. - 
PonA2 - R R S 
PonA2 + PonA2WT b n.d. - n.d - 
PonA2 + PonA2S398A b n.d. R n.d. S 
 
a   -   no change relative to wild-type   S     sensitized relative to wild-type 
    R  resistant relative to wild-type   n.d. not determined 
b “+” indicates that the second allele was expressed under the control of its native promoter from 
the attB locus after integration on the vector pMV306-G2. 
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activity by !-lactams.  These findings also illustrate the importance of H37Rv!rpfACDEB as a 
tool for the investigation of spontaneous resistance. 
 
Disruption of other PBPs confers only sensitivity to !-lactams 
The uniqueness of !-lactam resistance arising from PonA2 loss of function led us to 
wonder whether other PBP loss-of-function mutations could confer similar phenotypes.  We 
selected mutants containing insertions in ponA1, pbpA, and Rv2864c, which are the three other 
non-essential PBPs in MTB, from an arrayed transposon library.  Rv2864c and pbpA encode 
Class B HMW PBPs, while ponA1 encodes MTB’s remaining bifunctional 
glycosyltransferase/transpeptidase Class A HMW PBP.  We assayed these mutants for sensitivity 
to cefotaxime.  The pbpA mutant showed greatly increased susceptibility in its dose-response 
curve, while the ponA1 and Rv2864c mutants did not reproducibly differ from wild-type (Table 
4.3).  These phenotypes are not surprising; deletions of orthologous PBPs in the closely related 
organism Corynebacterium glutamicum produced similar changes, with very minor sensitization 
to some !-lactams and modest sensitization to others (27).  In no case in C. glutamicum did 
deletion of a PBP result in resistance (27). 
To evaluate the spectrum of !-lactams that showed similar behavior to the cephalosporin 
cefotaxime, we compared the responses of the PBP mutants to this cephalosporin with the 
responses to meropenem, a !-lactam of the carbapenem family, cloxacillin, a !-lactam of the 
penicillin family, and cephalexin, another cephalosporin (Table 4.3).  The pbpA mutant displayed 
increased sensitivity to all !-lactams tested, while ponA1 and Rv2864c did not show any 
reproducible phenotypes.  For ponA2, the null mutation was verified as cefotaxime-resistant as 
described above.  The ponA2 mutant was also resistant to cephalexin, but displayed increased 
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sensitivity to meropenem and no phenotype at all for cloxacillin (Figure 4.2, Table 4.3).  All of 
these ponA2 phenotypes could be suppressed by complementation with the wild-type ponA2 
allele but not the ponA2S398A catalytic null mutant. 
 
Screen for other factors affecting ceftriaxone sensitivity 
In Escherichia coli, protein interaction studies have shown interactions between Class A 
HMW PBPs, Class B HMW PBPs, lytic transglycosylases, and endopeptidases (28, 29).  These 
findings have led to the proposal that peptidoglycan synthesis proceeds through multienzyme 
complexes.  Related work in MTB has shown that PonA1, a Class A HMW PBP, interacts with 
an endopeptidase, RipA (25), which itself interacts with the lytic transglycosylase RpfB (30); 
this interaction indicates that although phylogenetically distant, MTB, like E. coli, may use 
multienzyme complexes to synthesize its own peptidoglycan (25). 
We wondered whether PonA2 might be acting in such a complex.  If so, loss of other 
genes encoding members of the complex might phenocopy loss of PonA2.  Alternatively, if loss 
of PonA2 was conferring cephalosporin resistance through some other functional pathway, 
perhaps by acting as a scaffolding protein or through its PASTA domain, it seemed possible that 
other genes might be involved in this functional pathway too. 
To address these possibilities, we screened an arrayed transposon library containing 
insertions in 2,500 MTB genes in 96-well plates in 31 µg/mL ceftriaxone.  Ceftriaxone is a 
cephalosporin that showed similar resistance profiles to cefotaxime for our panel of PBP mutants 
(data not shown).  The 31 µg/mL ceftriaxone concentration represents a concentration at which 
growth would be expected of H37Rv%ponA2, but not of wild-type H37Rv. 
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We grew the transposon mutants in duplicate 96-well plates in the presence of drug for 
14 days and then measured their growth by optical density.  To select hits, we calculated the Z 
score of each strain’s growth, for the high-drug condition, for the low-drug condition, relative to 
the population mean and standard deviation for its plate: 
Z = x ! µ
"
  
where x is the sample value, µ is the plate mean, and ) is the plate standard deviation.  We set a 
hit cutoff of Z > 3 to consider only transposon mutants that behaved significantly different from 
other mutants on the same plate.  We calculated Z scores across plates rather than across the 
screen to account for plate-to-plate variation. 
Seven genes showed significant growth at 31 µg/mL (Table 4.4).  These hits were 
resistant to ceftriaxone.  One of these six mutants carried an insertion in dacB2, a low-molecular 
weight PBP, which hydrolyzes rather than forms D,D peptide bonds in peptidoglycan.  The D,D 
carboxypeptidases, although they bind !-lactams, are not considered likely to be the targets 
whose inhibition leads to killing (8, 11); for this reason, we did not include them in our panel of 
PBPs in Table 4.3.  If DacB2 confers resistance through the same pathway as PonA2, it must act 
downstream of PonA2.  This follows from energetic considerations: transpeptidases like PonA2 
cannot form a new peptide bond without cleaving a preexisting one.  The substrate specificity of 
DacB2 is well-understood; it cleaves the D,D peptide bond that would act as the preexisting bond 
in PonA2-mediated transpeptidation.  Without that peptide bond, transpeptidation cannot 
proceed. 
Another strain contained a transposon insertion in Rv3680.  Since this gene is the first 
gene upstream of ponA2 on the 5! strand and encodes an ATPase anion exporter (31), we 
reasoned that it was unlikely to confer cefotaxime resistance by itself and was probably acting  
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Table 4.4. Transposon insertion locations conferring ceftriaxone resistance. 
 
Gene Namea Function 
Rv0169 mce1A unknown transmembrane protein 
Rv0626  antitoxin 
Rv1373  glycolipid sulfotransferase 
Rv2577  unknown 
Rv2911 dacB2 carboxypeptidase 
Rv3493c  unknown transmembrane protein 
Rv3680  probable anion transporter ATPase 
a
 Where blank, no gene name exists. 
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through polar effects on ponA2.  This result needs to be confirmed by complementation.  No 
transposon insertions in ponA2 itself were evaluated in the screen. 
A functional connection between the remaining five genes and ponA2 is less apparent.  
Three have undefined functions (Table 4.4).  One is a glycolipid sulfotransferase of undefined 
substrate specificity (31), and so it is difficult to speculate how its activity may contribute to 
ceftriaxone sensitivity.  The remaining gene is an antitoxin.  Antitoxins typically repress the 
activity of cognate toxins; in the case of Rv0626, the toxin is the downstream gene Rv0627, a 
ribonuclease that presumably affects mRNA stability of specific transcripts (32).  Typically, 
toxin-antitoxin systems represent a way for bacteria to respond to stressful conditions (32); the 
Rv0626 antitoxin is known to be downregulated during macrophage infection (33), which 
suggests that its cognate toxin actively affects the transcriptome in these conditions.  The genes 
affected by the Rv0627-Rv0626 system are not known. 
 
Screen for other factors affecting !-lactam resistance 
We had previously observed that loss of pbpA caused cefotaxime and meropenem 
sensitization.  We concluded that pbpA was necessary for intrinsic resistance to both !-lactams 
(Table 4.3).  As with PonA2, we sought to identify other genes that might act in the pbpA 
transpeptidation pathway. We repeated the screen of transposon insertion mutants, this time 
screening at subinhibitory antibiotic concentrations to identify sensitized genes.  We screened 
against both meropenem and ceftriaxone.  Screening conditions were identical to those used 
above, but with 2 µg/mL meropenem and 4 µg/mL ceftriaxone. 
Using the same significance cutoff of Z > 3, and averaging the results of the ceftriaxone 
and meropenem screens, we identified 18 genes that conferred sensitivity to both ceftriaxone and 
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meropenem (Table 4.5).  Six of these genes were undescribed conserved hypothetical coding 
sequences, while two encoded transcription factors of unknown specificity.  Several hits were in 
known cellular pathways with unclear relationships to peptidoglycan metabolism or !-lactam-
mediated killing (Table 4.5). 
One hit stood out as being of particular significance.  This was Rv3811, which encodes a 
secreted amidase.  In fact, this amidase is the only MTB member of the amidase family PF01510 
(31), of which Streptococcus pneumoniae lytA is another member.  In S. pneumoniae, lytA is an 
autolysin essential for bacteriolysis during penicillin-induced cell death (34).  LytA and other 
members of PF01510 cleave the bond between glycan strands and peptides in peptidoglycan, 
which can be useful during peptidoglycan recycling or to remove crosslinks in peptidoglycan 
(35).  The reason this amidase might confer resistance to !-lactams in MTB is unclear. 
 
Meropenem resistance in Mycobacterium smegmatis arises through a different mechanism 
 These experiments have shown that loss of both ponA2 and pbpA confers meropenem 
sensitivity in MTB.  We therefore hoped to pinpoint ponA2 or pbpA as the meropenem 
resistance-determining mycobacterial PBP.  It is difficult to perform experiments with 
meropenem and MTB because of the antibiotic’s short half-life in MTB growth medium, in 
comparison to the ~24 h doubling time of MTB.  Consequently, we switched to the model 
organism Mycobacterium smegmatis, a close relative of MTB with a ~3 h doubling time. 
As we did previously with cefotaxime, we hoped to identify mutations that conferred 
resistance by target site modification in the resistance determining PBP.  We isolated 
spontaneously meropenem-resistant mutants of M. smegmatis.  In contrast to the MTB 
cefotaxime resistance by loss of ponA2, which conferred resistance to cefotaxime but sensitivity  
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Table 4.5. Transposon insertion locations conferring !-lactam sensitivity. 
 
Gene Namea Function 
Rv0049  unknown 
Rv0204c  unknown transmembrane protein 
Rv0820 phoT inorganic phosphate transport 
Rv0821c phoY2 regulator of inorganic phosphate transport 
Rv1049  transcription factor 
Rv1124 ephC possible oxidative damage response 
Rv2349c plcC transmembrane phosphoesterase 
Rv2418c  unknown 
Rv2502c accD1 fatty acid metabolism 
Rv2645  unknown 
Rv3005c  possible sulfur oxidation 
Rv3183  transcription factor 
Rv3196A  unknown 
Rv3207c  unknown transmembrane protein 
Rv3406  possible small molecule catabolism 
Rv3524  transmembrane sensor 
Rv3787c  possible phosphatase regulator 
Rv3811  secreted amidase 
a
 Where blank, no gene name exists. 
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to meropenem, these mutants were resistant to both cefotaxime and meropenem (Figure 4.4, cf 
Figure 4.2).  No mutations were identified in the ponA2 or pbpA orthologs, although a poorly-
expressed ponA2 paralog was not checked.  The resistance was not due to changes in !-lactamase 
expression, since high doses of clavulanate did not eliminate the difference. This work shows 
that MTB may develop !-lactam resistance through other means than ponA2 loss of function. 
Work is still being performed to identify the causative mutations. 
 
Discussion 
We have shown that mutation of ponA2 confers cephalosporin resistance in MTB and 
that this resistance is recessive.  We have shown that these mutations function by loss or 
impairment of ponA2 function, and that loss of ponA2 function confers not only cephalosporin 
resistance, but also meropenem sensitivity. 
Our findings have implications for molecular models of !-lactam action.  Broadly, they 
show that each class of !-lactams has specific genetic determinants of sensitivity and resistance.  
This implies that the specific subset of transpeptidases through which each class induces cell 
death may differ.  Of particular interest is cephalexin: this cephalosporin, like piperacillin, is 
usually considered to be an FtsI-specific inhibitor, while other cephalosporins are not (36, 37); 
our findings clearly show that cephalexin, like the other cephalosporins, is rendered ineffective 
by ponA2 loss of function.  Cephalexin, ceftriaxone, and cefotaxime have greatly differing side 
chains, but the same core site mimicking the D-alanine-D-alanine substrate in pentapeptide side 
chains.  Since their susceptibility profiles against the various PBPs are the same, it seems likely 
that the core is responsible for their binding specificity.  The PonA2 active site has several  
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Figure 4.4. Susceptibilities of meropenem-resistant Mycobacterium smegmatis.  Clavulanate 
(open circles) inhibits the mycobacterial !-lactamase; any differences in dose-response 
relationships that persist in the presence of clavulanate are therefore not a result of differences in 
!-lactamase activity between strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122 
conserved structural motifs across its mycobacterial orthologs (11), which may determine its 
greater affinity for the cephalosporin core or lesser affinity for the carbapenem core. 
The ability of ponA2 loss of function mutations to confer recessive resistance show that 
ponA2 plays a unique role in !-lactam resistance.  To our knowledge, there is no precedent for 
the loss of a PBP conferring any level of !-lactam resistance in any organism.  We believe that 
loss of ponA2 must result in some sort of cellular adaptation under normal conditions that 
renders MTB more resistant to cephalosporins when it encounters them.  One such adaptation 
could be that loss of ponA2 leads to regulatory changes that result in its role being filled by a 
previously inactive cefotaxime-resistant, meropenem-sensitive transpeptidase (Figure 4.5).  We 
are currently trying to identify an upregulated transpeptidase in H37Rv%ponA2 by global 
transcriptional analysis.  Candidates include the L,D-transpeptidases, which are believed to bind 
carbapenems but not other classes of !-lactams, or one of the known PBPs.  Although we 
evaluated the known PBPs ponA1, pbpA, and Rv2864c for contributions to !-lactam 
susceptibility, only pbpA loss of function caused a change.  Loss of pbpA function resulted in 
sensitivity to both cefotaxime and meropenem, this gene does not seem to be a reasonable 
candidate for the cefotaxime-resistant, meropenem-sensitive transpeptidase; its presence 
contributes only to resistance, not to sensitivity.  We cannot eliminate the possibility that the 
replacement transpeptidase is encoded by ponA1 or Rv2864c; these mutants showed no shift in 
!-lactam susceptibility, which could result from as simple an explanation as a lack of expression 
under normal conditions. 
The discovery of mutations in the glycosyltransferase domain of PonA2 was initially 
surprising, but since glycosyltransferase activity is believed to be required for transpeptidase 
activity (11), and since loss of transpeptidase activity is sufficient to confer all of the observed 
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Figure 4.5. A model for responses to different !-lactams. When PonA2 is present (left panel) 
crosslinking of peptide strands proceeds, unless cephalosporins are present.  When 
cephalosporins are present, PonA2 is inhibited and death ensues.  When PonA2 is absent (right 
panel), its function is replaced by an alternate transpeptidase.  This peptidase crosslinks peptide 
strands normally unless carbapenems are present.  When carbapenems are present, this 
transpeptidase is inhibited, and without PonA2, death ensues. 
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phenotypes, it seems possible that the glycosyltransferase mutations acted by modulating the 
output of the transpeptidation function.  The dependence of the !-lactam sensitivity phenotypes 
on the activity of the transpeptidase domain was expected, since this activity is the target of the 
!-lactams.  The contribution that transpeptidase activity may give to heat stress tolerance is less 
clear.  In their original paper noting heat stress sensitivity in a ponA2-transposon-disrupted 
strain, Vandal et al. speculated that stronger peptidoglycan might be required to withstand heat 
(24); the transpeptidase activity certainly contributes to the netlike properties that impart 
structural integrity to the peptidoglycan macromolecule. 
The findings have important implications for the development of resistance in a clinical 
context.  Transposon insertions in ponA2 cause attenuation in mouse lungs and spleens (24).  
Therefore, resistance through loss of ponA2 function would result in attenuation.  But these 
results suggest that complete loss of PonA2 function is not necessary for resistance; partial 
resistance can be acquired by very minor substitutions, such as the one-carbon change from 
aspartate to glutamate.  Although these mutations confer only very small changes in 
cephalosporin susceptibility, a series of such mutations can create an opportunity for clinically 
relevant resistance (38).  Furthermore, the finding that changes leading to cephalosporin 
resistance can engender meropenem sensitivity strongly suggests that !-lactams are not all 
equivalent in treatment, and that there are potential gains from treatment with multiple !-lactams.  
This is consistent with emerging data that carbapenems may act against L,D-transpeptidases (17).  
The great differences among MTB mutants in susceptibility to different !-lactams underline the 
diversity within this antibiotic family and the vast potential it contains for future tuberculosis 
treatment. 
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Section 4.3: Materials and methods 
Strains and growth conditions 
Mycobacterium tuberculosis H37Rv and its derivatives were grown to mid-logarithmic 
phase at 37 °C in 30 mL sterile square containers; culture aeration was maintained by shaking at 
100 RPM with a constant head space of 20 mL.  Alternatively, cultures were grown in 1 L 
cylindrical containers with aeration maintained by rotation at 2 RPM with a head space of greater 
than 900 mL.  For Mycobacterium smegmatis, cultures were grown in 250 mL Erlenmeyer 
flasks; culture aeration was maintained by shaking at 250 RPM with a constant head space of 
200 mL. 
 The growth medium was Middlebrook 7H9 Broth supplemented with Middlebrook 
OADC Enrichment (Becton Dickenson #212351), 0.2 % glycerol, and 0.05 % Tween 80.  For 
Mycobacterium smegmatis, Middlebrook OADC Enrichment was omitted and replaced with 
equivalent concentrations of albumin, dextrose, and sodium chloride. 
 
Genetic manipulation of Mycobacterium tuberculosis 
 Cells in the logarithmic phase of growth – OD600 0.5 – 1.0 – were centrifuged at 2,850 x 
g 10 min 37 °C, washed twice in 10 % glycerol 0.05 % Tween 80, and resuspended in 1/10 
volume of the same solution. 
 The inducible multicopy plasmid pUV15tetORm (39), the integrating single-copy 
plasmid pMV306-G2, and the PCR product %ponA2 (Table 4.1) were introduced to M. 
tuberculosis H37Rv by electroporation of 1 µg DNA in a 1 mm electroporation cuvette at 2.5 
kV, 8 µF, 1 M(. 
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 The integrating single-copy plasmid pMV306-G2 was derived from pMV306 (40) as 
follows: the small fragment from pNEB193 (New England BioLabs) released by EcoRI and 
XbaI was cloned into the PacI site followed by the small fragment from SalI and HindIII 
digestion cloned into the PmeI site.  The resulting construct was digested with SgfI and BspHI to 
introduce the zeocin resistance cassette an unpublished plasmid (a generous gift of E Rubin). 
 Cells were recovered from electroporation in 5 mL 7H9 in otherwise normal growth 
conditions for 24 h.  They were then plated on 7H10 agar medium supplemented with 
Middlebrook OADC Enrichment, 0.5 % glycerol, and 0.05 % Tween 80.  After 18 – 24 d, single 
colonies were cultured.  For %ponA2, a further selection was performed on these isolates, using 
7H10 agar medium as described above, with 5 % sucrose, to eliminate the recombineering 
plasmid. 
 
Isolation of spontaneous resistant mutants 
 Cultures in the logarithmic phase of growth were plated onto 7H10 agar medium 
supplemented with Middlebrook OADC Enrichment, 0.5 % glycerol, and 0.05 % Tween 80.  For 
cefotaxime (Sigma-Aldrich C7912), the concentration used to select resistant mutants was 25 
µg/mL.  For meropenem (LKT Laboratories M1770), the concentration used was 11 µg/mL. 
 
Heat stress assay 
 Cells were pelleted at 2,850 x g and washed in 7H9 medium twice.  They were then 
resuspended to OD600 0.05.  Cell densities at time zero were assessed by colony-forming unit 
(CFU) plating.  Cells were diluted 1/10 into fresh 7H9 medium and incubated at 45 °C for 24 h.  
Cell densities were again assessed by CFU plating, with a limit of detection of 10 CFU/mL.  All 
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CFU measurements were performed in triplicate, and results are representative of two 
independent experiments.  Heat stress survival was calculated as a percentage of CFU in the 
culture at time zero. 
 
Dose-response curves 
 Compounds were stored at -20 °C in dimtheyl sulfoxide (DMSO) or -80 °C in 7H9 
medium.  The potency of compounds was determined as follows: 384-well plates were filled 
with 20 µL 7H9 medium per well; if a compound in a DMSO stock was being tested 384-well 
plates were filled with 20 µL 7H9 medium and 1 % or 2 % DMSO.  Compounds were arranged 
in the plates in twofold dilutions from the highest compound concentration to the lowest. 
 MTB grown to mid-logarithmic phase (OD600 0.5 – 1.0) was centrifuged at 58 x g to 
remove clumps and then diluted in fresh 7H9 medium to OD600 0.1.  Cells were added in 20 µL 
aliquots to each well, with individual strains being measured in quadruplicate, sextuplicate, or 
octuplicate. 
 Cells were grown for 100 – 200 hr at 37 °C in sealed containers.  After incubation, 
growth was measured by OD600.  The IC90 was identified for each singlicate dilution series as the 
lowest concentration at which OD600 was less than 10 % of the growth in the absence of drug; for 
combinations of strain and drug for which singlicate measurements yielded different results, a 
range was reported.  In additional to these technical duplicates, all strain and drug combinations 
were tested in at least two independent experiments.  Although absolute numbers differed 
between experiments due to variation in drug stocks, differences between strains remained 
constant. 
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 Where dose-response curves were measured with an inducible promoter, strains were first 
grown to OD600 0.5 – 1.0, diluted to OD600 0.025 in fresh medium in the presence of 
anhydrotetracycline, and incubated for 7 d using normal growth conditions.  Afterward, dose-
response curves were prepared normally, but medium contained anhydrotetracycline.  
Anhydrotetracycline was added from a 100 ng/µL 95 % ethanol stock, to a final concentration of 
0.125 ng/µL, a concentration empirically judged to be noninhibitory. 
 
Transposon library screens 
Screen – Transposon mutants were incubated in 7H9 medium in 96-well paltes for 7 days 
at 37 °C to an OD600 of 0.05 – 0.20.  The cells were mixed, and aliquots of 5 µL were transferred 
to 96-well screening plates containing 95 µL 7H9 medium and the following drug 
concentrations: [1] no drug; [2] 31 µg/mL ceftriaxone (Sigma-Aldrich C5793); [3] 4 µg/mL 
ceftriaxone; [4] 42 µg/mL meropenem; [5] 2 µg/mL meropenem.  These plates were incubated 
for 14 days at 37 °C, after which growth was measured by OD600. 
Analysis – Duplicates were averaged.  Z scores were calculated for each plate using the 
plate mean and standard deviation of bacterial growth as assessed by OD600.  To calculate 
sensitization, Z scores were calculated from the difference between the growth of each strain in 
the presence and absence of low drug. 
 
Whole-genome sequencing 
 Genomic DNA was prepared from RPFnull as follows: cells were spun at 2,850 x g and 
resuspended in 1 mL of the supernatant.  They were heated to 100 °C for 15 min.  The cells were 
spun at 2,100 x g 20 min and resuspended in 0.95 mL bug lysis solution: 25 mM Tris pH 7.9, 10 
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mM EDTA, 0.9 % dextrose.  The cells were spun at 16,100 x g 10 min, then resuspended in 0.5 
mL bug lysis solution containing 1 mg/mL lysozyme.  Cells were incubated at 37 °C 20 h.  100 
µL 10% SDS was used to terminate the reaction and 50 µL Proteinase K (New England BioLabs 
P8102) was added.  This mixture was heated to 55 °C for 20 min.  200 µL 5 M NaCl was added.  
To this mixture, 160 µL cetrimide solution was added: 4.1 % NaCl, 10 % cetrimide.  This 
mixture was heated to 65 °C 10 min.  DNA was extracted with 1 mL 24:1 chloroform:isoamyl 
alochol.  Phase separation was achieved with centrifugation at 16,100 x g 5 min; the extraction 
was repeated.  800 µL aqueous phase was extracted and mixed with 560 µL 2-propanol.  This 
was incubated at room temperature for 5 min and then spun at 16,100 x g 5 min.  The 
supernatant was aspirated and 1 mL 70 % ethanol added, followed by mixing by inversion.  This 
mixture was spun at 16,100 x g 5 min and then air-dried.  DNA was resuspended in 50 µL TE pH 
7.8.   Whole-genome sequencing was performed by Texas A & M University using Illumina 
technology. 
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Chapter 5: Discussion 
 
Section 5.1: Summary of results 
 
 When this research began, the peptidoglycan-degrading enzymatic function of the 
resuscitation-promoting factors (RPFs) had just come to light (1).  It was also known that 
deletion of multiple RPFs could deleteriously affect survival in mouse models of tuberculosis 
infection (2).  In fact, several separate RPF deletion mutants showed attenuated survival in 
macrophages (2, 3), in persistence in mice, and in reactivation from a mouse model of latent 
infection (4). 
 The connection between all of these infection-related phenotypes and the specific 
enzymatic function of RPFs was unclear, since they are collectively dispensable for in vitro 
growth (2).  One hypothesis was that RPFs might act to resuscitate cells from dormancy by 
releasing the cell from a tightly restrictive peptidoglycan shell, similar to the emergence from the 
spore state in Bacillus subtilis (5).  Another hypothesis was that RPFs might release 
peptidoglycan fragments as signaling molecules, which would then stimulate emergence from 
the dormant state (5). 
 These models explained how peptidoglycan degradation might affect resuscitation, but 
they did little to explain why a Mycobacterium tuberculosis (MTB) strain lacking four RPFs 
could not establish infection, let alone escape from the latent phase.  The connection between the 
biochemical peptidoglycan degradatory function and survival during infection intrigued us. 
 The results of our chemical screen suggested a new physiological role for the RPFs 
linking their biochemical function to their in vivo phenotypes.  Specifically, it showed that the 
RPFs are essential for maintaining the low permeability of the MTB mycolic acid layer.  The 
chemical screen showed that the RPFs were required for tolerance to a wide array of small 
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molecules.  Some of these molecules retained activity against RPF-deficient strains even when 
their chirality was inverted, which indicated that they acted through means other than enzyme 
inhibition.  Others were active against both RPF-deficient strains and human erythrocytes, which 
also strongly suggested a common mechanism of potentiation against the RPF-deficient strains. 
 We focused on the cephalosporin class of !-lactam antibiotics, which contained many 
members with activity against RPF-deficient strains.  We showed that the cephalosporins have 
specific bactericidal activity against RPFnull, a strain lacking all five MTB RPFs.  We showed 
that this activity can be partially suppressed by complementation of RPFnull with rpfC, rpfD, and 
rpfE.  This finding supports growing evidence that the RPFs have some degree of functional 
redundancy (6).  To elaborate the mechanism by which these RPFs affected sensitivity to 
cephalosporins, we then showed that one cephalosporin, cefamandole, has enhanced access to 
the protected periplasmic compartment of MTB in the RPFnull strain; we showed this by 
demonstrating that cefamandole can be depleted from growth medium more rapidly by the 
periplasmic !-lactamase activity of the RPFnull strain than the wild-type strain, even though the 
!-lactamase activity itself is constant.  To verify that this phenotype is RPF-related, we showed 
that it can be suppressed by addition of rpfC, rpfD, and rpfE. 
Vulnerability to multiple antibiotics and unclassified small molecules suggests that the 
RPFnull strain might have some general, common mechanism that enhances the activity of each 
of these molecules.  The enhanced access of cefamandole to the periplasmic compartment 
indicates that this general mechanism of enhanced activity might be a change in the permeability 
of the outer mycolic acid layer of the MTB cell wall.  This change in permeability could explain 
the in vivo survival defects of RPFnull and other RPF-deleted strains.  Specifically, macrophages 
control MTB infection with soluble small molecules such as reactive oxygen and nitrogen 
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species (7, 8), and the intact outer membrane permeability barrier is thought to be essential for 
low permeability against these types of small, hydrophilic solutes (9).  Its disruption or 
impairment would be devastating for the progress of infection, which is consistent with the poor 
survival of RPFnull in vivo (2). 
The investigation of the cephalosporins led us naturally to the question of how these 
molecules might act.  The precise links between the inhibition of the peptidoglycan synthetic 
machinery by !-lactams and subsequent !-lactam-induced cell death and bacteriolysis are an area 
of ongoing research (10), and especially so in mycobacteria, for which even less is known about 
peptidoglycan growth, maintenance, and degradation than in better-studied model organisms 
(11).  We used RPFnull to study !-lactam resistance in MTB, since the high intrinsic resistance of 
MTB to !-lactams makes study with the wild-type organism challenging in laboratory 
conditions. 
Spontaneous mutants of RPFnull acquired cephalosporin resistance by mutation of the 
gene ponA2, a penicillin-binding protein (PBP).  We showed a causal link between mutations 
spanning both the glycosyltransferase and transpeptidase domains of ponA2, a range of 
mutations that has not been shown to cause !-lactam resistance in other organisms.  We showed 
that these mutations were recessive and that they conferred heat stress sensitization, a phenotype 
associated with ponA2 loss of function.  These findings suggested that the ponA2 mutations 
might be conferring resistance through ponA2 loss of function.  We created a ponA2  deletion 
(ponA2null) mutant and found that this mutant displayed even more cephalosporin resistance than 
the spontaneous mutants.  All together, these findings establish loss of PBP function as a 
mechanism of !-lactam resistance. 
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Since !-lactam resistance by PBP loss of function is unusual, we wondered whether loss 
of any other MTB PBPs could also confer resistance.  We tested transposon insertion mutants in 
ponA1, pbpA, and Rv2864c, the remaining nonessential PBP genes in MTB.  The results of these 
tests showed that intact pbpA was required for full resistance to all !-lactams tested, while ponA1 
and Rv2864c disruption did not result in any phenotypes.  Only ponA2 conferred a resistance 
phenotype upon disruption.  Interestingly, ponA2 deletion conferred not only cephalosporin 
resistance, but meropenem sensitivity.  This finding allows us to conclude that the different !-
lactams have highly different binding profiles in MTB. 
 To expand upon these observations, we performed a transposon screen to identify other 
genes that might play a role in !-lactam resistance.  We found a low-molecular weight PBP, 
dacB2, whose disruption also conferred resistance to ceftriaxone.  A number of other genes 
whose disruption conferred resistance encoded conserved hypothetical proteins. 
 To find genes that, like pbpA, were required for cephalosporin and carbapenem 
resistance, we screened the transposon library for mutants that could not grow in subinhibitory 
concentrations of either of these two antibiotics.  Among the genes that were sensitized to both 
antibiotics was Rv3811, a secreted amidase that is a distant ortholog of lytA, the Streptococcus 
pneumoniae autolysin essential for !-lactam-induced bacteriolysis. 
 
Section 5.2: Current conclusions and future questions 
 The demonstration that ponA2 and dacB2 can confer !-lactam resistance by loss of 
function necessitates a new model for a mechanism of !-lactam resistance.  Some organisms, 
such as Staphylococcus aureus, can resist !-lactam-induced cell death so long as they have a 
single !-lactam-resistant transpeptidase activity.  In S. aureus, this is the inducible, !-lactam-
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refractory PBP2a; so long as PBP2a is functional, the presence of other transpeptidases is 
irrelevant (12).  In contrast, in MTB, the presence of ponA2 transpeptidase activity confers 
sensitivity rather than resistance. 
 Despite this apparent contrast, the methicillin resistance in S. aureus provides a hint of 
the simplest explanation for ponA2-mediated cephalosporin resistance in MTB.  PBP2a is not 
normally expressed in S. aureus; instead, it is induced by the !-lactam sensor protein BlaR1 (13).  
This happens quickly enough to rescue the cell from death during !-lactam treatment.  From the 
perspective of peptidoglycan, the sequence of events is that first, peptidoglycan crosslinking 
stops as the !-lactam-sensitive PBPs are inhibited.  Then, PBP2a is induced and crosslinking 
resumes, while the normal PBPs become irrelevant because !-lactam binding has rendered them 
catalytically inactive and hindered. 
 We propose that like S. aureus, MTB has two states.  The first is a vulnerable state where 
!-lactams bind the available PBPs and, without some response by the cell, ultimately lead to 
death.  The second is a resistant state where a !-lactam insensitive PBP, like PBP2a, carries on 
peptidoglycan crosslinking and the cell is safe.  The difference between S. aureus and MTB is 
that in MTB, the resistant state can only be achieved by the loss of ponA2; after deletion of 
ponA2, the !-lactam-refractory PBP is expressed and the bacterium is safe.  When ponA2 is 
present, no transpeptidase is induced upon exposure to !-lactams, ponA2 and other extant PBPs 
are inhibited, and the cell dies. 
 This theory makes testable predictions.  Genetically, it predicts that there exists another 
transpeptidase gene that, if deleted, will suppress cephalosporin resistance in ponA2.  
Biochemically, it predicts the appearance of a new carbapenem-binding activity in a ponA2 
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knockout compared to wild-type MTB.  We are searching for the transpeptidase by trying to 
identify upregulated RNA transcripts in the ponA2 knockout. 
 One provocative possibility is that the upregulated transpeptidase is an L,D-
transpeptidase.  MTB possesses numerous genes encoding L,D-transpeptidases (14), and current 
research indicates that they are generally cephalosporin-resistant and meropenem-sensitive (15).  
If this possibility were true, it would be highly significant, because it would show the 
replacement of 4!3 crosslinking by PBPs with 3!3 crosslinking by L,D-transpeptidases.  This 
has only been demonstrated once before, in Enterococcus faecium (16).  In that species, this 
replacement conferred resistance to ampicillin (16). 
 The resistant state need not involve the upregulation of an L,D-transpeptidase, or even a 
transpeptidase at all; there are many ways that MTB could acquire cephalosporin resistance, of 
which we have provided a detailed overview in Chapter 1.4.  For example, the loss of ponA2 
could somehow lead to the upregulation of a cephalosporin-resistant efflux pump or, through 
altered protein-protein interactions, to a decrease in the cephalosporin affinity of another existing 
PBP; the ability of protein-protein interactions to affect PBP !-lactam affinity has also been 
observed in E. faecium (17).  We prefer the L,D-transpeptidase hypothesis because the 
upregulation of one transpeptidase is an intuitively appealing response to the loss of another. 
 Regardless of the specific mechanism of resistance, one fact is clear: loss of ponA2 leads 
to some adaptation in the molecular physiology of the cell that renders it cephalosporin-resistant.  
In order for loss of ponA2 to lead to such an adaptation, the cell must have some way of sensing 
the loss of ponA2.  This method could be indirect, through sensing of the downstream molecular 
products of PonA2 activity, direct, through protein-protein interactions with PonA2, or a 
combination of the two. 
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 An example of an indirect mechanism would be the Escherichia coli Amp system.  PBP 
transpeptidation leads to the removal of the terminal D-Ala in peptidoglycan peptide stems, so 
the Amp system reimports a sampling of peptidoglycan degradation products and detects the 
ratio of D-alanylated peptide stems to non-D-alanylated peptide stems (18).  Changes in this ratio 
indicate a change in PBP activity.  MTB does not possess orthologs to the genes of this particular 
system (14), but it is an example of an indirect PBP sensing system. 
 A direct mechanism of sensing PonA2 would be the physical interaction of PonA2 with a 
transmembrane sensor.  We are not aware of any specific examples of an interaction of a PBP 
with a transmembrane sensor, but no theoretical considerations preclude such a possibility. 
 If direct interaction is involved, existing knowledge better supports a combination 
mechanism of direct and indirect sensing.  For example, direct interaction of the PonA2 paralog 
PonA1 with a partner endopeptidase has been clearly demonstrated; PonA1 not only interacts 
with this partner endopeptidase, RipA, but modulates its activity (19).  In a combination 
mechanism, the PBP-partner interaction is the direct component, while the indirect component 
would be the effect that this interaction has on the downstream products of the partner’s activity.  
The partner could be an endopeptidase, like RipA, or any of a number of other peptidoglycan-
modifying enzymes. 
 The sensing of and subsequent cellular response to the loss of ponA2 raise a fundamental 
question: what is the difference between chemical inhibition of function and genetic loss of 
function (Figure 5.1)?  Why does the cell respond to total loss of the ponA2 gene, but when it is 
faced with the much simpler problem of the inhibition of PonA2 by cephalosporins, it fails to 
respond adequately and dies? 
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Figure 5.1. Schematization of the differing responses of wild-type and ponA2 deletion strains to 
cephalosporin treatment.  In the wild-type, chemical inhibition of PonA2 by cephalosporin 
treatment leads to cell death.  Genetic deletion of ponA2, rather than leading to cell death also, 
leads to some sort of adaptation.  Not only does this adaptation allow the cell to survive, it also 
renders it resistant to future cephalosporin treatment. 
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 There are two ways to account for the difference.  One is that the difference is timing.  
The other is that cellular adaptation to ponA2 loss of function is not related to its transpeptidase 
activity. 
Regarding timing, the ponA2null mutant had a chance to adapt to conditions of gradually 
diminishing PonA2, as the protein was diluted over many generations after the removal of the 
source gene from the parent cell.  In contrast, inhibition of PonA2 by !-lactam exposure in a 
culture, except at very low concentrations, occurs very rapidly in comparison to the doubling 
time of MTB.  The physiological consequences of !-lactam exposure may become irreversible 
before the cell has a chance to respond to the inhibition of its peptidoglycan synthetic machinery.  
The biological difference that accounts for the different concentrations at which the wild-type 
and mutant die, in this scenario, is that death in the mutant occurs in a bacterium that had the 
chance to adapt to diminished PonA2 over generations, while in the wild-type, death occurs 
before such adaptation. 
 The other way to account for the difference is that the stimulus for cellular adaptation to 
ponA2 loss of function could be loss of some other function than transpeptidation.  One 
candidate function could involve PonA2’s PBP and serine/threonine kinase-associated (PASTA) 
domain; this domain is also found in an MTB transmembrane protein kinase, where it is believed 
to act as a periplasmic sensor (20).  Another candidate function could involve the glycosyl-
transferase activity of PonA2, which is not inhibited by !-lactams.  However, if loss of the 
glycosyltransferase or PASTA functions were responsible for adaptation, restoration of these 
activities without transpeptidation should suppress cephalosporin resistance.  Our experiments 
showed a transpeptidase catalytic null ponA2 allele did not suppress cephalosporin resistance. 
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Finally, the loss of function that stimulates adaptation to ponA2 deletion could involve a 
scaffolding role for PonA2, as with PonA1 and RipA above.  In such a scenario, loss of 
interaction with a partner protein would occur in the ponA2null mutant, but not upon chemical 
inhibition of PonA2. 
 Regardless of the particular differences between genetic and chemical loss of ponA2 
function, there are several significant implications of our research.  (1) The acquisition of 
cephalosporin resistance implies some cellular response to the loss of ponA2, possibly the 
upregulation of an alternate transpeptidase.  (2) The existence of such a response implies a 
mechanism of sensing active PonA2, which may involve detection of the protein itself or its 
synthetic products.  (3) This mechanism of sensing cannot be completely explained by existing 
concepts because it involves the ability to distinguish inhibition of transpeptidation from its 
genetic ablation. 
 The nature of the cellular response to loss of ponA2 and the mechanism by which it is 
sensed are open scientific questions.  Their answers can only lead to an enhanced understanding 
of the complicated field of peptidoglycan metabolism. 
 
Section 5.3: Concluding remarks 
This project began with an inquiry into the cellular function of the resuscitation-
promoting factors.  During the course of our work, some researchers have developed small 
molecule inhibitors of the RPFs.  Our work, which showed that one cellular function of the RPFs 
is to protect against a broad array of small molecules, indicates that inhibition of RPFs may 
potentiate many of these small molecules.  Indeed, since RPFs are required for in vivo survival, 
the RPF inhibitors have the potential to be useful therapeutic agents on their own. 
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Among the agents that RPFs potentiate against, cephalosporins and other !-lactams are a 
critical element of the current pharmaceutical armamentarium against non-tuberculosis 
respiratory infections.  This work shows that the primary in vitro route to cephalosporin 
resistance is ponA2 loss of function.  Since ponA2 loss of function attenuates M. tuberculosis 
(20), cephalosporins may have potential to overcome the problem of drug resistance in a 
pathogen that has total drug resistance to first-line therapeutic agents (21). 
  The unexploited potential of the cephalosporins and other !-lactams against 
tuberculosis, and the desperate need for new therapeutic agents against this disease, bespeak 
possibilities of a future where the hyperbolic language of “magic bullets” once used to describe 
penicillin and streptomycin might again become relevant. 
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Appendix 1: Electron microscopic studies of H37Rv#rpfACDEB and related strains 
A (H37Rv, logarithmic phase) 
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B (H37Rv, carbon-starved) 
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C (H37Rv%rpfACDEB, logarithmic phase) 
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D (H37Rv%rpfACDEB, carbon-starved) 
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E (H37Rv%rpfACDEB ponA2G1328T, logarithmic phase) 
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F (H37Rv%rpfACDEB ponA2G1328T) 
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 We separately collected clonal populations of H37Rv%rpfACDEB, its parent H37Rv 
strain, and H37Rv%rpfACDEB ponA2G1328T, a cefotaxime-resistant spontaneous mutant daughter 
strain of H37Rv%rpfACDEB, under two conditions: 
 1. exponential growth – OD600 0.6 – 0.8 
 2. carbon starvation – grown to OD600 0.6 – 0.8, washed and resuspended in PBS with 
0.05 % tyloxapol at OD600 0.2, incubated at 37 °C for 4 weeks 
 We collected the cells by centrifugation, washed in PBS with 0.05 % Tween 80, and then 
resuspended in a fixative containing 2 % paraformaldehyde, 2.5 % glutaraldehyde, and 0.1 M 
sodium cacodylate at pH 7.4.  Fixed cells were subjected to transmission electron microscopy by 
the Harvard Medical School Department of Cell Biology core facility. 
 The results do not present obvious differences between H37Rv and its daughter RPF-
depleted strains.  The slightly granular appearance of the H37Rv%rpfACDEB strain in this image 
does not appear consistently across samples (see second image in (C)). 
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Appendix 2: Biochemical studies of PonA2 activity 
 
 
We expressed PonA2 (lane 2) and the PonA2R81G (lane 3) and PonA2W443S (lane 4) 
isoforms from the pET-28a vector in Escherichia coli BL21-DE3 cells.  We induced constructs 
expressing each isoform and the parent construct (lane 1) for 1 hr in cells growing at 37 °C 250 
RPM with 1 mM IPTG.  We lysed the cells by beadbeating, pelleted inclusion bodies, and then 
collected membranes by centrifugation at 100,000 x g 1 hr; we stained the collected membranes 
with 10 µM bocillin, for 90 min.  The flanking dark bands of the gel are from a protein ladder; 
they occur at 75 kDa and result from the fluorescence of the marker.  These results indicate that 
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the wild-type PonA2 isoform expresses in a catalytically active form at these conditions to a 
much greater extent than either of the mutant isoforms. 
 
This "-His Western blot, tagging the PonA2 protein using the pET-28a endogenous histidine tag, 
shows the induction of PonA2W443S in soluble form under a variety of conditions.  From left to 
right: ladder, 37 °C 1 mM IPTG, 300 µM IPTG, 100 µM IPTG, 30 µM IPTG, no IPTG, and 30 
°C 1 mM IPTG, 300 µM IPTG, 100 µM IPTG, 30 µM IPTG.  The left blot shows cell lysates 
after the removal of inclusion bodies by centrifugation; the circled band corresponds to the 75 
kDa position for 30 °C 30 µM IPTG.  The right blot shows the same lysates before the removal 
of inclusion bodies. 
 These results indicate that although PonA2W443S is abundantly expressed, it has a 
tendency to form inclusion bodies.  Together, these blot results and the results of the bocillin 
staining experiment above show that mutant PonA2 isoforms may be less catalytically active and 
have fundamentally different solubility characteristics from the wild-type isoform, supporting 
our hypothesis that these alleles may lead to PonA2 that is impaired in function. 
 
 
 
 
 
 
 
